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 Summary  IV
As two leading female cancers, breast cancer, especially metastatic breast cancer, and ovarian 
cancer, have brought an increasing health and economic burden globally. Biomarkers could 
improve patient outcomes and quality of life because they play vital roles in cancer screening, 
diagnosis, prognosis, and prediction. Metabolites are promising cancer biomarkers, as they 
represent the ultimate phenotypic alteration of the organism and are closely related to cancer. 
Plasma metabolites can be accessed with minimally invasive procedures. Using plasma 
metabolites as biomarkers for cancer and other diseases has been widely explored because of 
the possibility of repeated sampling and periodic monitoring of blood samples. However, 
metabolic studies are still in their infancy, and only a few studies with large sample sizes are 
available so far. In this thesis project, we explored the potential of metabolites as putative 
diagnostic and prognostic markers in breast and ovarian cancer. 
Plasma metabolite profiling and subsequent validation in primary breast cancer 
patients and healthy controls identified 18 metabolites that were significantly differentially 
represented (FDR < 0.05). Multivariate logistic regression analysis selected a panel of seven 
metabolites to discriminate primary breast cancer patients from healthy controls with an AUC 
of 0.80. If this panel of metabolites identified here could be verified in large prospective 
study cohorts, this panel, including Glu, Orn, Thr, Trp, Met-SO, C2, and C3, might add value 
to multi-molecular diagnostic marker sets for breast cancer early detection.  
The association of plasma metabolites with metastatic breast cancer was investigated 
as well. Metastatic breast cancer patients with high numbers of circulating tumor cells 
(termed CTC-positive) and those with low numbers or without CTCs (termed CTC-negative) 
were analyzed and compared to healthy controls as well as primary breast cancer patients. 
Lists of 19 and 12 metabolites were identified to significantly distinguish CTC-positive and 
CTC-negative samples from healthy controls, respectively. A panel comprising His, C4:0, 
C18:1, lysoPC a C18:2, PC aa C40:6, and PC ae C42:3 for CTC-positive patients with AUC 
= 0.92, and a combination of Asn, Glu, His, Thr, Trp, C16:0, C18:0, C18:1, C18:2, lysoPC a 
C18:2, and PC aa C40:6 for CTC-negative patients with AUC = 0.89 were selected to 
distinguish from healthy controls. Significantly different metabolites between CTC-
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positive/CTC-negative and primary breast cancer patients exhibited significant overlaps with 
those between CTC-positive/CTC-negative patients and healthy controls. 
We also investigated the prognostic value of metabolites in metastatic breast cancer 
patients. After successive analysis of the discovery and validation cohorts, four metabolites 
were found to be significantly negatively correlated with progression-free survival, while 12 
metabolites were negatively correlated with overall survival. Amongst these metabolites 
associated with survival, LASSO Cox regression analysis selected a combination of PC ae 
C36:1 and PC ae C38:3 to predict progression-free survival, and a combination of lysoPC a 
C20:3, lysoPC a C20:4, PC aa C38:5, PC ae C38:3, and SM (OH) C22:2 to predict overall 
survival. Even though the proposed metabolic signatures showed a lower prognostic power 
than the CTC status, an FDA-approved prognostic marker, the combination of the Cox 
selected metabolites with the CTC status displayed a lower integrated prediction error than 
CTC status alone. Therefore, the identified metabolic markers might add prognostic value in 
combination with other biomarkers such as CTC status determination. The majority of the 
here identified metabolites have previously shown functional roles in cancer and metastasis 
development, thus laying a supposed mechanistic basis for their differential levels observed 
in plasma. 
Lastly, comparative profiling of plasma metabolites in ovarian cancer patients and 
healthy controls were applied to identify metabolites associated with ovarian cancer. 
Remarkably, 71 significantly differentially expressed metabolites were identified (FDR < 
0.05). Most of them were down-regulated in ovarian cancer patients. A combination of seven 
metabolites, including His, Trp, C18:1, lysoPC a C18:2, PC aa C32:2, PC aa C34:4, PC ae 
C34:3, were identified to differentiate ovarian cancer cases from healthy controls with an 
AUC of 0.95. Furthermore, this panel could distinguish ovarian cancer from primary breast 
cancer patients with an AUC of 0.93.  
In conclusion, we identified specific signatures of plasma metabolites associated with 
primary breast cancer, metastatic breast cancer, and ovarian cancer. Further, we identified 
sets of metabolites correlated with the prognosis of metastatic breast cancer patients. If these 
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identified metabolic marker signatures can be verified in large, multi-centric, prospective 
studies, they might add value to the development of blood-based diagnostic tests.  
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 Zusammenfassung V
Als führende Krebserkrankungen bei Frauen haben Brustkrebs und Eierstockkrebs weltweit 
zu einer zunehmenden gesundheitlichen und wirtschaftlichen Belastung geführt. Ovarialkrebs 
und metastasierender Brustkrebs weisen zudem eine sehr schlechte Prognose auf. Biomarker 
könnten den Behandlungserfolg und die Lebensqualität der Patientinnen verbessern, indem 
sie eine wichtige Rolle bei der Krebsvorsorge, Diagnose, Prognose und Vorhersage spielen. 
Metaboliten sind vielversprechende Krebs-Biomarker, da sie eine endgültige phänotypische 
Veränderung des Organismus darstellen und in enger Beziehung zur Krebsentstehung und 
Progression stehen. Der Zugang zu Plasmametaboliten ist minimal invasiv und aufgrund der 
Möglichkeit einer wiederholten Probenentnahme und der regelmäßigen Überwachung von 
Blutproben vielversprechend. Metaboliten-basierte Biomarkerstudien für Krebsdiagnostik 
und Prognose befinden sich jedoch noch in einem frühen Stadium, da bislang nur wenige 
Studien mit umfassenden Probenzahlen und /oder optimaler Blutplasmaproben-Prozessierung 
vorliegen. In diesem Dissertationsprojekt untersuchten wir das Potenzial von Metaboliten als 
mutmaßliche diagnostische und prognostische Marker für Brust- und Eierstockkrebs.  
Das Plasmametaboliten-Profiling und die anschließende Validierung bei primären 
Brustkrebspatientinnen und gesunden Kontrollpersonen identifizierte 18 Metaboliten, die 
signifikant unterschiedlich in den beiden Gruppen vertreten waren (FDR <0,05). Durch eine 
multivariate logistische Regressionsanalyse konnte eine Gruppe von sieben Metaboliten (Glu, 
Orn, Thr, Trp, Met-SO, C2 und C3) ausgewählt werden, die Patientinnen mit primärem 
Brustkrebs von gesunden Kontrollen mit einer AUC von 0,80 unterscheiden kann. Sofern die 
hier identifizierten Metaboliten in großen prospektiven Studienkohorten verifiziert werden 
können, könnten diese zur Entwicklung von multimolekularen diagnostischen Markersätzen 
für die Brustkrebs Früherkennung beitragen. 
Die Assoziation von Plasmametaboliten mit metastasierendem Brustkrebs wurde 
ebenfalls untersucht. Patientinnen mit metastasierendem Brustkrebs, die eine erhöhte Anzahl 
zirkulierender Tumorzellen (als CTC-positiv bezeichnet) aufwiesen und solche mit einer 
geringen Anzahl oder ohne CTCs (als CTC-negativ bezeichnet) wurden analysiert und mit 
gesunden Kontrollpersonen sowie Patientinnen mit primärem Brustkrebs verglichen. Es 
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wurden 19 bzw. 12 Metabolite identifiziert, um CTC-positive bzw. CTC-negative MBC 
Proben signifikant von gesunden Kontrollen zu unterscheiden. Zur Unterscheidung von CTC-
positiven MBC Patienten von gesunden Kontrollen wurde ein Panel bestehend aus His, C4:0, 
C18: 1, lysoPCa C18:2, PC aa C40:6 und PC ae C42:3 identifiziert (AUC = 0,92) und für 
CTC-negative Patienten eine Kombination aus Asn, Glu, His, Thr, Trp, C16:0, C18:0, C18:1, 
C18:2, lysoPC a C18:2 und PC aa C40:6 (AUC = 0,89) ausgewählt. Signifikant 
unterschiedliche Metaboliten zwischen CTC-positiven/CTC-negativen metastasierenden 
Brustkrebspatientinnen und primären Brustkrebspatientinnen zeigten signifikante 
Überschneidungen mit denen o.g. zwischen CTC-positiven/CTC-negativen metastasierenden 
Patientinnen und gesunden Kontrollpersonen.  
Wir untersuchten auch den prognostischen Wert von Metaboliten bei Patientinnen 
mit metastasierendem Brustkrebs. Nach sukzessiver Analyse der Entdeckungs- und 
Validierungskohorten wurde festgestellt, dass vier Metaboliten signifikant negativ mit der 
progressionsfreien Überlebensrate korrelierten, während 12 Metaboliten negativ mit dem 
Gesamtüberleben korrelierten. Via LASSO Cox-Regressionsanalyse wurde eine Kombination 
aus PC ae C36:1 und PC ae C38:3 identifiziert, um eine progressionsfreie Überlebensrate 
vorherzusagen, und eine Kombination aus lysoPC a C20:3, lysoPC a C20:4, PC aa C38:5, PC 
ae C38:3 und SM (OH) C22:2 um eine Vorhersage zum Gesamtüberleben zu treffen. Obwohl 
die vorgeschlagenen metabolischen Signaturen eine niedrigere Prognoseleistung als der CTC-
Status, ein von der FDA zugelassener Prognosemarker, aufwiesen, konnte durch die 
Kombination der durch die Cox Analyse ausgewählten Metaboliten mit dem CTC-Status ein 
geringerer integrierter Prognosefehler als mit dem CTC-Status allein erzielt werden. Daher 
könnten die identifizierten Metabolitenmarker in Kombination mit anderen Biomarkern wie 
der CTC-Statusbestimmung die prognostische Aussagekraft erhöhen.  
Zuletzt wurden Plasmametabolite identifiziert, die mit Ovarialkrebs assoziiert sind. 
Bemerkenswerterweise wurden zwischen Proben von Ovarialkrebspatientinnen und gesunden 
Kontrollen 71 signifikant unterschiedlich exprimierte Metaboliten identifiziert (FDR <0,05). 
Die meisten von ihnen waren bei Patientinnen mit Ovarialkarzinom herunterreguliert. Eine 
Kombination von sieben Metaboliten (His, Trp, C18:1, lysoPC a C18:2, PC aa C32:2, PC aa 
C34:4, PC ae C34:3) wurde identifiziert, um Ovarialkrebsfälle von gesunden Kontrollen zu 
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unterscheiden (AUC = 0,95). Darüber hinaus konnte dieses Panel Eierstockkrebs von 
primären Brustkrebspatientinnen mit einer AUC von 0,93 unterscheiden.  
Zusammenfassend konnten wir spezifische Signaturen von Plasmametaboliten 
identifizieren, die mit primärem Brustkrebs, metastasiertem Brustkrebs und Eierstockkrebs 
assoziiert sind. Darüber hinaus identifizierten wir Metabolitensätze, die mit der Prognose 
metastasierender Brustkrebspatientinnen korrelieren. Sofern diese identifizierten 
metabolischen Markersignaturen in großen, multizentrischen, prospektiven Studien verifiziert 
werden können, könnten sie zur Entwicklung von Blut-basierten diagnostischen 
Markersätzen beitragen. 
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1. Introduction 
 Cancer  1.1
Cancer is a collection of more than 100 related diseases that can start almost anywhere in the 
body and characterize by the feature of the abnormal and uncontrollable proliferation of cells. 
Carcinogenesis involves a series of complex and dynamic processes consisting of three stages: 
initiation, progression, and metastasis (Wang et al., 2017). Biological capabilities acquired during 
the complex, multistep development of human tumors are defined as the hallmarks of cancer, 
which was proposed by Hanahan and Weinberg in 2000 (Hanahan and Weinberg, 2000). Later in 
2011, another four emerging hallmarks were supplemented (Hanahan and Weinberg, 2011), and 
the ten hallmarks are shown in Figure 1.1. Cancer is a genetic disease. Genetic changes, which 
regulate cell cycle and cell homeostasis, result in an imbalance between cell proliferation and cell 
death, leading to tumorigenesis (Weinberg, 2014). Cancer-causing mutations primarily include 
point mutations, as well as chromosomal structural alterations and loss of heterozygosity (Loeb 
and Loeb, 2000). Cells that gain these cancer-causing mutations and stimulate tumor formation 
are defined as tumor-initiating cells (TIC) (Qureshi-Baig et al., 2017). Tumors can be either 
benign or malignant. The ability to invade nearby tissues and spread to distant sites is an 
important criterion to distinguish malignant tumors from benign tumors. Metastases spawned by 
malignant tumors are responsible for almost all deaths from cancer (Sopik and Narod, 2018). In 
addition to the tumor cells, tumor niche within the tumor microenvironment (TME) is closely 
connected to the process of tumorigenesis, from pre-malignant to a malignant state and facilitates 
tumor growth (Wang et al., 2017). Based on the tissue of origin, cancer in humans can be 
classified into five principal types: carcinoma (epithelial tissues), sarcoma (connective tissue), 
leukemia (blood cells of bone marrow), lymphoma and multiple myeloma (immune system), and 
neuroectodermal tumors (brain and spinal cord) (Weinberg, 2014).  
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Figure 1.1: The Hallmarks of Cancer. Ten functional properties of tumor cells required for 
complete malignant transformation are essential. (Adapted from Hanahan and Weinberg, Cell, 
2011, Hallmarks of cancer: the next generation). 
 
Cancer is a major public health problem worldwide and is the second leading cause of death 
in the United States (Siegel et al., 2018). Cancer was responsible for an estimated 8.1 million 
new cancer cases, and 9.6 million deaths in 2018 alone, about 1 in 6 deaths is due to cancer 
globally (Bray et al., 2018). The commonly diagnosed cancer cases were lung cancer (11.6%), 
female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) (Bray et 
al., 2018). Prevention, screening, diagnosis, prognosis, and tumor development or spread 
targeted therapies are strategies for cancer management and treatment (Gralow et al., 2008).  
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 Breast Cancer 1.2
1.2.1 Epidemiology and Detection  
Breast cancer is cancer that arises from the breast tissue, and most of the breast cancer cases 
are adenocarcinomas. Breast cancer continues to be the most prevalent malignancy and a 
major cause of human mortality in women worldwide. It accounts for 24.2% of all newly 
diagnosed cancer cases and 15% of all cancer-related deaths among females in 2018 (Figure 
1.2) (Bray et al., 2018). Due to the availability of early detection and treatment, the incidence 
rates in high-income countries are higher than those in low- and middle-income countries, 
whereas the mortality rates are lower in high-income countries than those in low- and middle-
income countries (Torre et al., 2017). In Germany, breast cancer causes the highest cancer-
related morbidity and mortality rates in females, with percentages of 25.9% and 17.6%, 
respectively (Figure 1.2) (Bray et al., 2018). These high numbers have indicated the urgency 
and importance of breast cancer study in the field of cancer research.    
Currently, mammography is the standard technique for breast cancer screening and 
detection, and it was reported to have high detection sensitivity (93%) for breast cancer 
patients with symptoms (Jiang et al., 2016). However, mammography is far less effective for 
early-stage breast cancer detection and is less sensitive among women with high breast 
density and young women (Buist et al., 2004; Tabar et al., 1995). Moreover, mammography 
has only a minor effect on the reduction of breast cancer mortality (Bleyer and Welch, 2012; 
Broeders et al., 2012). Besides, the x-ray radiation from mammography adds up over time 
does harm to the breast (Miglioretti et al., 2016). Other screening methods, including self or 
clinical examination, breast ultrasound, and magnetic resonance imaging, have their pros and 
cons (Elmore et al., 2005).   
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Figure 1.2: Incidence and mortality numbers and rates of female cancer worldwide and in 
Germany in 2018. Data source: GLOBOCAN 2018 ( http://gco.iarc.fr/).   
 
1.2.2 Classification  
Breast cancer is a highly heterogeneous disease that has long been noted in histology and 
clinical outcomes, which serve as the basis for disease classification (Polyak, 2011). Since the 
subtypes of breast cancer differ a lot in outcomes and responses to treatment (Taherian-Fard 
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et al., 2015; Viale, 2012), breast cancer classification and characterization are substantially 
crucial for a better understanding of the disease and the treatment of individuals with 
precision medicine. There are four major routinely used breast cancer classification methods 
in the clinic, as shown in Figure 1.3.   
Based on the tumor cells of origin, breast cancer can be classified into different 
histological subtypes. As reported by the latest World Health Organization (WHO) guidelines, 
20 major and 18 minor tumor types, including benign, carcinoma in situ, malignant invasive 
carcinomas, and sarcomas, are recognizable (Tavassoéli, 2003). Among these histological 
subtypes, invasive ductal carcinoma (IDC) is the most common, representing 75% of all 
cancer cases. The second common is invasive lobular carcinoma (ILC), accounting for 
around 10% of all cancer patients (Li et al., 2005).    
The grading system, which indicates the differentiation extent of tumor cells, is based on 
the microscopic appearance of the tumor section. The Nottingham grading system is currently 
the most widely recommended method for breast cancer grading (Bloom and Richardson, 
1957). According to tubule formation, nuclear pleomorphism, and mitotic count, tumors are 
classified into well-differentiated (low grade, Grade 1), moderately differentiated 
(intermediate grade, Grade 2), and poorly differentiated (high grade, Grade 3) (Bloom and 
Richardson, 1957).  
The staging system was proposed by the American Joint Committee on Cancer (AJCC) 
in 1959 for the first time, and from then on, it has been updated continuously as 
understandings of disease refreshed (Edge S et al., 2010). The AJCC system classified cancers 
with three criteria, tumor size (Tx, Tis, T0, T1-T4), lymph node number (Nx, N0-N3), and 
distant metastasis (Mx, M0, M1), which is known as the TNM staging system (Edge S et al., 
2010). Breast tumors include stages 0, I, II, III, and IV according to these three TNM 
pathological features, and the prognosis becomes worse as the stages increase. The five-year 
survival rate is 100% for stage 0 and stage I patients, 93% for stage 2, 72% for stage 3, and 
decrease to 22% for patients with stage IV breast cancer (Howlader N et al., 2019).  
The immunohistochemical recognition of hormone receptors, including estrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 
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(HER2/neu), classifies breast cancer into four molecular subtypes (Schnitt, 2010), i.e. 
Luminal A (ER+ and/or PR+, HER2-, low grade), Luminal B (ER+ and/or PR+, HER2-, high 
grade), HER2 amplified, and basal or triple-negative (ER-/PR-/HER2-). The molecular 
subtype of breast cancer determines its progression and treatment response. From Luminal A, 
Luminal B, HER2 amplified to triple-negative, cancer growth rate increase, as well as cancer 
aggressiveness, while cancer prognosis becomes continuously worse (Schnitt, 2010). Besides 
these four molecular subtypes, some other subtypes, such as Claudin-low and normal-like 
breast cancer, have been proposed (Malhotra et al., 2010). Determination of the subtype of 
breast cancer is vital for making treatment decisions, specifically for those that target 
hormone receptors, and improving patient management.  
 
 
Figure 1.3: Major classification methods of breast cancer.  
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1.2.3 Risk Factors 
Breast cancer is a result of the interplay of diverse genetic and environmental factors. 
Approximately 75% of breast cancer cases are sporadic, while the remaining 25% are 
familial/hereditary (Anderson, 1992). The risk factors of breast cancer can be classified as 
genetic risk factors and non-genetic risk factors.  
 
Genetic Risk Factors 
Genetic and familial factors can substantially increase the lifetime risk of developing breast 
cancer and are associated with the development of cancer at a young age. Women with any 
first-degree relative with breast cancer have about twice the risk of developing breast cancer 
(Pharoah et al., 1997). Approximately 30% of breast cancer cases are attributed to hereditary 
factors (Mavaddat et al., 2010; Turnbull and Rahman, 2008). BRCA1, a DNA-repair gene, 
was the first established major breast cancer susceptibility gene. BRCA2 is another gene of 
the same family, and they cause most of the hereditary breast carcinoma (Hall et al., 1990). 
Women with inherited mutations in BRCA1 or BRCA2 genes are at particularly high risk. 
Carriers of BRCA1 mutations have a 55%-60% chance for developing breast cancer during 
their lifetime, whereas those with BRCA2 mutations have a lower risk of 45% (Foulkes and 
Shuen, 2013; Malone et al., 1998). Besides these two genes, TP53, PTEN, and 
STK11/LKB1are also essential susceptibility genes that involve in the hereditary and familial 
forms of breast cancer (Nathanson et al., 2001). Genetic low-penetrance risk factors 
contribute much more modest (2 ~ 4 fold) risks of breast cancer (Thompson and Easton, 
2004). 
 
Non-genetic Risk Factors 
Age is the most potent risk factor for breast cancer. The incidence of breast cancer increases 
with age, doubling every ten years until menopause and is usually diagnosed in the 50 ~ 60 
age group (Allison, 2012; McPherson et al., 2000). Reproductive factors and hormones are 
also established risk factors for breast cancer, such as earlier menarche, later menopause, 
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nulliparity, delayed childbearing, no breastfeeding, and hormone exposure (McPherson et al., 
2000). Also, a personal history of breast disease, benign breast diseases such as fibrosis and 
hyperplasia are other non-modifiable risk factors for breast cancer (McPherson et al., 2000). 
At last, unhealthy lifestyles are also associated with breast cancer incidence, e.g., alcohol 
drinking, smoking, physical inactivity, excess body weight (postmenopausal females), and 
high-dose radiation to the chest, particularly at a young age (Verma et al., 2012).  
 
1.2.4 Metastatic Breast Cancer 
Around 25%-30% of primary breast cancer (PBC) cells leave their original primary site and 
migrate to distant sites, which is called metastatic or stage IV breast cancer (Lorusso and 
Ruegg, 2012; Redig and McAllister, 2013). Approximately 10%-15% of PBC patients 
develop metastasis within three years. However, metastatic manifestation after ten or more 
years from initial diagnosis was also reported (Weigelt et al., 2005). Breast cancer cells tend 
to metastasize to essential organs in humans, such as bone and liver, also less frequently to 
lung and brain (Lee, 1985).  Most of the breast cancer-related deaths are due to metastasis, 
rather than the primary ones. Since our understanding of metastasis mechanism is inadequate, 
most of the metastatic cancers are still incurable.  
 
Evolution of metastasis theories 
The term metastasis was coined in 1829 (JC, 1829), and understandings of cancer metastasis 
evolved from time to time in nearly two hundred years (Dong et al., 2009; Talmadge and 
Fidler, 2010). In 1889, a London surgeon Stephen Paget proposed the famous “seed and soil” 
hypothesis to explain the usual organ-specific metastasis pattern (Paget, 1989). Forty years 
later, in 1928, James Ewing suggested that metastasis occurs purely through an anatomic 
mechanism (Ewing J, 1928). In 1975, Irwin Bross et al. proposed the metastatic cascade for 
sequential events needed for disseminated cancer (Nicolson and Winkelhake, 1975). Then the 
clonal selection and expansion model was proposed by Peter Nowell and Isalah Fidler in 
1976 (Fidler and Kripke, 1977; Nowell, 1976). Until in 2001, the role of cancer stem cells 
(CSC) in metastasis was proposed by Irving Weissman et al. (Reya et al., 2001). Then the 
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next year, Rene Bernard and Robert Weinberg raised a progression puzzle to challenge the 
traditional view of metastasis. The dual proclivity model was subsequently proposed 
(Bernards and Weinberg, 2002).  At the same time, Jean Paul Thiery used the epithelial-
mesenchymal transition (EMT) phenomenon to explain metastatic progression (Thiery, 2002). 
In 2006, Kent Hunter et al. emphasized the role of genetic susceptibility for metastatic 
propensity (Hunter, 2006). Figure 1.4 shows a brief evolution timeline of metastasis theories.      
 
 
Figure 1.4: The evolution of metastasis theories. The timeline outlines the major conceptual 
advances in the origins and mechanisms of metastasis from Paget’s seminal “seed vs. soil” 
hypothesis to more recent theories regarding the role of cancer stem cells and early 
developmental transitions. (Adapted from Dong, F. et al., clinical cancer research, 2009, 
Translating the metastasis paradigm from scientific theory to clinical oncology.) 
 
Mechanism of metastasis 
Integration of the metastasis theories in nearly two hundred years, the current model for 
cancer metastasis proposed by Christine L. Chaffer and Robert A. Weinberg is shown in 
Figure 1.5 (Chaffer and Weinberg, 2011). In general, cancer metastasis is a two-phase 
process. The first phase is known as the metastasis cascade, which involves the physical 
translocation of cancer cells from the primary tumor to a distant organ and colonization of the 
translocated cells within the new organ. The second phase encompasses the ability of the 
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cancer cell to develop into a metastatic lesion at that distant site (Chaffer and Weinberg, 
2011). During these processes, circulating tumor cells (CTC), tumor cells traveling through 
the circulating, play a vital role in establishing cancer metastasis (Reya et al., 2001).   
During metastasis, primary epithelial tumor cells have to leave their extracellular matrix 
and establish metastasis at a distant organ, during which their morphologies alter. The 
hypothesis of mechanism that promotes detachment and migration is the epithelial-
mesenchymal transition (EMT). EMT, which plays critical roles in early embryonic 
morphogenesis (Thiery et al., 2009), can help tumor cells transit from the epithelial state to 
the mesenchymal state. Once tumor cells reach the target site, the mesenchymal phenotype 
reverts to the epithelial state via mesenchymal-to-epithelial transitions (Chaffer and Weinberg, 
2011). EMT program induction during tumorigenesis needs various signaling pathways 
between cancer cells and stromal cells nearby, such as transforming growth factor β (TGF-β), 
receptor tyrosine kinases, Wnt-β-catenin, Notch, and bone morphogenetic protein (Gonzalez 
and Medici, 2014).  
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Figure 1.5: The Processes of cancer metastasis. (Adapted from Christine L. Chaffer and 
Robert A. Weinberg, Science, 2011, A perspective on cancer cell metastasis) 
 
 Ovarian Cancer 1.3
1.3.1 Epidemiology 
Ovarian cancer (OVCA) is cancer that arises from the ovary. It is the eighth leading in cancer 
incidence and mortality in women worldwide, representing 3.4% of all newly diagnosed 
cancer cases and 4.4% of all cancer-related deaths among females in 2018 (Figure 1.2)(Bray 
et al., 2018). Among all gynecological cancers, ovarian cancer is the third most common 
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cancer after cervical and uterine cancer and is associated with the second-worst prognosis and 
the second-highest mortality rate (Bray et al., 2018). In Germany, ovarian cancer is the ninth 
most common cancer, but the fifth highest in mortality rate, with percentages of 2.4% and 
4.9%, respectively (Figure 1.2). In most developed countries, ovarian cancer remains the 
leading cause of death among gynecological cancers (Siegel et al., 2018). Such a high 
mortality rate is due to the asymptomatic and secret growth of ovarian cancer, which delays 
the onset of symptoms. Besides, the absence of effective screening and early detection 
methods result in its diagnosis in the advanced stages (Momenimovahed et al., 2019). As a 
result, ovarian cancer is called the “silent killer” (Momenimovahed et al., 2019).  
 
1.3.2 Classification 
Ovarian cancer is highly heterogeneous that encompasses a collection of neoplasms with 
distinct histological and molecular features and prognosis (Gilks and Prat, 2009). Ovarian 
cancer has a variety of subtypes. Currently, there are two conventional classification methods 
for ovarian cancer (Figure 1.6).  
Cells of origin: Based on the cells of origin and histogenetic principles, the WHO 
classified ovarian cancer into three main classes of tumors: epithelial tumors, stromal tumors, 
and germ cell tumors (Kurman, 2014). Epithelial tumors represent around 90% of all ovarian 
cancer cases, which form on the outer layer of the ovaries. Epithelial ovarian tumors can be 
further classified into histological types as follows: serous, mucinous, endometrioid, clear cell, 
transitional cell tumors (Brenner tumors), carcinosarcoma, mixed epithelial tumor, 
undifferentiated carcinoma, and others (Kaku et al., 2003; Kurman, 2014). Among these 
subtypes, serous tumors are the most common ones. Around 7% of ovarian cancers are 
stromal, which begins in the tissue that contains hormone-producing cells. Another category 
is the germ cell tumor that starts in egg-producing cells, which is rare and usually occurs in 
younger women (Kaku et al., 2003; Kurman, 2014).  
FIGO staging: For patient outcome prediction and treatment plan determination, the 
basic principle to refer to is cancer staging. The International Federation of Gynecology and 
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Obstetrics (FIGO) Committee on Gynecologic Oncology has a staging system for ovarian 
cancers since 1973 (Prat and Oncology, 2014). The FIGO stages ovarian cancer surgically 
and pathologically by detecting the tissue samples from ovaries, pelvis, and abdomen. 
Ovarian cancer is thus classified into four stages, namely stages I, II, III, and IV, as shown in 
Figure 1.6 (Javadi et al., 2016).  
 
 
Figure 1.6: Major classification methods of ovarian cancer.  
 
According to the data released by the Surveillance, Epidemiology, and End Results 
(SEER) program, the five-year survival rates for ovarian cancer vary for the different cell of 
origin subtypes (Table 1.1) (Howlader N et al., 2019). For women with the disease is 
confined to the ovary at diagnosis, cure rates are as high as above 90%. Even when the tumor 
extends to other pelvic structures or develops into primary peritoneal cancer, the five-year 
survival rates are still higher than 70%. However, it decreases to lower than 20% for patients 
with advanced stage. One main reason for the high mortality rate of ovarian cancer is that 
over 70% of ovarian cancer cases are detected at the late stage when it has the worst 
prognosis and causes most of the deaths (Rauh-Hain et al., 2011). Therefore, early detection 
of ovarian cancer is of significance in disease management and survival improvement.  
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Table 1.1: Five-year survival rates of ovarian cancer patients with different subtypes (data 
source: SEER, 1975-2016). 
Five-year survival rates of ovarian cancer 
FIGO staging Epithelial tumors Stromal tumors Germ-cell tumors 
Stage I 90% 95% 98% 
Stage II 70% 78% 94% 
Stage III 39% 65% 87% 
Stage IV 17% 35% 69% 
 
1.3.3 Risk Factors 
The risk factors of ovarian cancer are almost the same as that of breast cancer, which also 
includes genetic and non-genetic factors. The most significant genetic risk factor for ovarian 
cancer is the inherited mutations in BRCA1 or BRCA2, which account for around 5%-15% of 
all ovarian cancer cases (Lynch et al., 2013). Compared to women without BRCA1/BRCA2 
mutations, carriers of BRCA1 mutations have a 65% higher ovarian cancer risk, while women 
with BRCA2 mutations have a risk of up to 35% higher (Ingham et al., 2013; Mavaddat et al., 
2013). Similar to breast cancer patients, high-risk factors of ovarian cancer patients are 
familial and personal history (Momenimovahed et al., 2019).  Older age is the leading risk 
factor, especially for women over 65 years old, which largely reflects the accumulation of 
DNA mutations (Mohammadian-Hafshejani et al., 2017). Other factors like early age at 
menarche, late age at menopause, nulliparity, reproductive organ surgery, no contraception, 
hormone therapy, and unhealthy lifestyles, e.g., low physical exercise, smoking, alcohol, and 
high body mass index (BMI) in premenopausal women are all associated with the risk of 
ovarian cancer (Daniilidis and Karagiannis, 2007; Momenimovahed et al., 2019).       
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 Metabolomics  1.4
“Genomics and proteomics tell you what might happen, but metabolomics tells you what 
actually did happen.” 
                                                                   ─ Bill Lasley, University of California, Davis. 
In the “omics” family, metabolomics is the newest omics technology after genomics, 
epigenomics, transcriptomics, and proteomics, and is the endpoint of the pyramid (Dettmer 
and Hammock, 2004).  Metabolomics is the technique in system biology to qualitatively or 
quantitatively measure and analyze the metabolome changes associated with specific 
physiological and pathophysiological processes (Beger, 2013; Psychogios et al., 2011). The 
metabolome is the sum of all small-molecule (molecular weight less than 1500 Da) chemicals 
within cells, tissues, liquid biopsies, or the entire organism (Wikipedia). Metabolites are 
produced from metabolism, and they involve in many important biological processes, such as 
energetic regulation, enzyme activity control, structure build-up, and signaling (Vinayavekhin 
et al., 2010). Metabolic alterations are thought to be the downstream end products of 
expression alterations in genes or proteins. Metabolic variations reflect not only changes in 
individual genetic phenotypes and molecular physiology but also environmental influences 
(Beger, 2013). In this respect, metabolomics has the most significant advantage over the other 
omics technologies, the most predictive ability for the phenotypic properties could help to 
elucidate the nature and identity of the biological processes (Capati et al., 2017).   
Metabolic alterations caused by certain diseases could be detected in biological fluids 
before the clinical symptoms manifest because the cascade of small changes in enzyme 
activities could amplify the signal, which could be detected on the metabolite level (Capati et 
al., 2017). As a consequence, metabolomics is a promising method for disease biomarkers 
study. Indeed, metabolomics has attracted much attention in the discovery of biomarkers for 
disease diagnosis and prognosis (Wang et al., 2018a). 
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1.4.1 Cancer Metabolism  
Metabolic reprogramming, which is characterized by enhanced nutrient uptake to support 
biosynthetic, bioenergetics, and redox demands of malignant cells, is one of the hallmarks of 
cancer (Boroughs and DeBerardinis, 2015). Many metabolic processes are altered in cancer 
cells, tissues, or biofluids, resulting in measurable changes in metabolites that can be used as 
biomarkers to indicate the presence of cancer or its activity (Vazquez et al., 2016). The most 
classical metabolic pathway in cancer is aerobic glycolysis, rather than mitochondrial 
oxidative phosphorylation, which generates the energy needed for cellular processes in 
normal cells. Aerobic glycolysis in cancer is known as the “Warburg effect” (Vander Heiden 
et al., 2009; Warburg, 1956). In addition to glucose metabolism, glutamine metabolism is 
another fuel that supports cancer growth (Boroughs and DeBerardinis, 2015). Other amino 
acid metabolisms in cancer cells also play important roles. For instance, the oxidation of the 
branched-chain amino acids (BCAAs) isoleucine and valine provide an anaplerotic flux in 
some tissues (DeBerardinis and Chandel, 2016; Tonjes et al., 2013). Fatty acid metabolism is 
another common metabolic change in cancer cells that participate in membrane biosynthesis, 
lipidation reactions, and cellular signaling, which render as potential targets (DeBerardinis 
and Chandel, 2016). For example, the widely expressed transmembrane protein CD36 that 
facilitates fatty acid uptake is one of the targets in breast cancer. What is more, the decreased 
levels of CD36 in stromal tissue are associated with tumorigenesis initiation (DeFilippis et al., 
2012).  
Redox balance is also an essential feature of cancer cells. During tumorigenesis, reactive 
oxygen species (ROS) increased their production, which can be as high as a toxic level. 
Accordingly, glutathione oxidation-reduction, coupled to NADPH reduction-oxidation, is a 
major antioxidant pathway in cancer cells to cope with this (Boroughs and DeBerardinis, 
2015; Vazquez et al., 2016). The fundamental reason behind metabolic alterations of cancer 
cells can be attributed to the alterations in gene expression, as well as the metabolic enzyme 
activities (DeBerardinis and Chandel, 2016; Hart et al., 2016).   
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1.4.2 Metabolomics Techniques  
Currently, there are two standard identification techniques for metabolomics: nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). NMR spectroscopy 
uses isotopes processing property of magnetic spin, providing solution-state molecular 
structures information based on atom-centered nuclear interactions (Marion, 2013). MS 
involves an initial separation of metabolites from biological samples using chromatography 
(capillary electrophoresis (CE), gas chromatography (GC), liquid chromatography (LC) or 
ultra-high performance liquid chromatography (UPLC)) base on their mass to charge ratio, 
then identified with a tandem mass spectrometer (Feng et al., 2008). However, the pre-
separation stage is not always necessary. 
Each technique has its strengths and weaknesses but gives complementary information 
(Zhang et al., 2012). As summarized in Table 1.2, NMR is more reproducible, simple sample 
preparation, non-destructive, faster, quantitative, and less expensive, while MS has higher 
sensitivity, needs less sample, and gives more chemophysical information (Aboud and Weiss, 
2013; Capati et al., 2017; Hart et al., 2016; Zhang et al., 2012).  
 
Table 1.2: Summary of the advantages and disadvantages of NMR and MS techniques. 
 Features  NMR spectroscopy  MS 
Reproducibility  Very good 
Possible variation introduced 
by preparation 
Sensitivity  
Less sensitive 
(LOD: 100 µM 
≈100 metabolites) 
Very sensitive 
(LOD: 100 nM 
>1000 metabolites)  
Sample amount 
More sample is required 
(500 µl) 
Less sample is required 
(1-10 µl) 
Sample intervention Non-destructive Destructive  
Sample preparation  
Minimal   
(no separation required) 
Extensive (separation required, 
but not always) 
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Structural information High  Low  
Time consume  ~ 10 minutes  ~ 30 minutes 
Quantification  Easy  Difficult  
Chemophysical 
information 
Less information  
More information  
(time separation) 
Cost  Less expensive  Expensive 
 
So far, no technique could detect the whole metabolome. According to the aim of the 
investigation, one of the two approaches is used in metabolomics study: targeted or 
untargeted (Menni et al., 2017; Suhre and Gieger, 2012). The untargeted metabolomics 
technique detects previously unpredicted metabolic alterations associated with a specific 
disease, which is vital for identifying new biomarkers or novel mechanisms. The untargeted 
metabolomics usually uses NMR in hypothesis-generating studies that compare different 
groups (Menni et al., 2017; Suhre and Gieger, 2012). The targeted metabolomics technique 
involves hypothesis-driven experiments and is characterized by measuring sets of metabolites 
that are predefined and involve in a few metabolic pathways of interest. This approach mostly 
employs MS and has advantages of easily chemical identification, higher sensitivity, and 
absolute metabolite quantification (Menni et al., 2017; Patti et al., 2012). As a result, the 
typical method for metabolomics is to use NMR spectroscopy for untargeted screening and 
explore interesting pathways. Then employ MS to detect specific metabolites with low 
concentrations in a targeted way.  
 
 Tumor Markers   1.5
As defined by the National Cancer Institute, a tumor marker is “a substance found in tissue or 
blood or other body fluids that may be a sign of cancer or certain benign (noncancer) 
conditions. Most tumor markers are made by both normal cells and cancer cells, but they are 
made in larger amounts by cancer cells” (NCI Dictionary of Cancer Terms). Various tumor 
markers can be classified into the following categories according to their functions:  
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1) Screening markers are used to assess the cancer risk, distinguish individuals that are 
predisposed to particular types of cancers from the population. Typically, these 
markers are associated with genetic or epigenetic alterations. For instance, mutations 
of genes BRCA1 or BRCA2 indicates a higher risk of breast and ovarian cancer 
(Mavaddat et al., 2013).  
2) Diagnostic markers detect whether a specific tumor exists or not. For example, 
elevated levels of cancer antigen CA125 and CA19-9 could indicate ovarian cancer 
and pancreatic cancer, respectively (Haglund, 1986).   
3) Prognostic markers can be useful in predicting the course of tumor progression or 
outcomes and evaluating the survival chance of cancer patients. Tumor progression 
can be disease-free survival (DFS), distant disease-free survival (DDFS), 
progression-free survival (PFS), or overall survival (OS). In this project, we will 
emphasize PFS, a period that the disease remains stable, and OS, time from 
diagnosis to death.  
4) Predictive markers can predict patients’ responses to a particular treatment and help 
to decide the treatment plans. For example, the HER2 status of breast cancer patients 
is needed to determine the usage and efficacy of trastuzumab treatment.  
These tumor markers play essential roles in decision-making and tumor management, 
which have been demonstrated of significant clinical relevance.  
 
1.5.1 Tumor Markers for Breast Cancer  
Since breast cancer is a heterogeneous disease, no universal biomarker is available currently 
to diagnose and predict all types of breast cancer. Well-studied biomarkers for breast cancer 
can be categorized into several groups. Hormone receptors, including estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor family (HER2/neu), 
are the most important markers that assist in making treatment decisions (Harris et al., 2007). 
However, none of them has satisfactory diagnostic ability because they are not expressing in 
all breast cancer patients. Proliferation markers, such as Ki67, p53, cyclin D or E, 
differentially expressed in breast cancer cells, are potential prognostic markers.  
Introduction  36 
 
However, they are not sufficiently recommended for the route clinical assessment of breast 
cancer (Harris et al., 2007; Weigel and Dowsett, 2010). The emerging multigene expression 
tests, such as the commercially available MammaPrint test and Oncotype DX, as well as 
Rotterdam Signature, have been developed as breast cancer prognostic markers (Harris et al., 
2007; Paik et al., 2004; van 't Veer et al., 2002).  
Well-established circulating markers, such as carbohydrate antigens CA15-3, CA27-29, 
and carcinoembryonic antigen (CEA), are important prognostic markers and are routinely 
used to monitor MBC relapse and treatment efficacy. However, they are not used for PBC 
screening or diagnosis (Bast et al., 2001; Ludwig and Weinstein, 2005). The American 
Society of Clinical Oncology (ASCO) recommended urokinase plasminogen activator (uPA) 
and plasminogen activator inhibitor-1 (PAI-1) for determining prognosis in patients with 
newly diagnosed, lymph node-negative breast cancer (Harris et al., 2007). However, they are 
only recommended when imaging results are available due to the limit of accuracy, so they 
are not recommended for MBC (Guadagni et al., 2001; Lumachi et al., 2000; Uehara et al., 
2008). Other circulating tumor markers, such as metabolites and the US Food and Drug 
Administration (FDA) approved prognostic marker CTCs, will be discussed in the following 
sections.  
 
1.5.2 Tumor Markers for Ovarian Cancer  
Carcinoembryonic antigen (CEA) was the first described single serum marker for epithelial 
ovarian cancer in 1976 (Khoo and Mackay, 1976). Cancer antigen 125 (CA125) is the most 
studied serum biomarker for serous epithelial ovarian cancer (Muinao et al., 2018). It was 
approved by the FDA in 1981 to monitor cancer for women with a known diagnosis of 
ovarian cancer, rather than for preoperative use, nor associated with a survival benefit 
(Ueland, 2017). However, CA125 has sensitive of 47% for patients at their early stages, but a 
sensitivity of 80%-90% at the late stages (Colakovic et al., 2000; Hogdall, 2008). Moreover, 
CA125 expresses not only in ovarian cancer but also in breast cancer, colon cancer, 
endometrial cancer, and pancreatic cancer. Around 20% of ovarian cancer patients do not 
Introduction  37 
 
have CA125 expressed at all (Muinao et al., 2018). Thus, CA125 is not a specific biomarker. 
As a supplement to CA125, human epididymis protein 4 (HE4) was cleared by the FDA in 
2009 as a serum biomarker to monitor patients with a known diagnosed epithelial ovarian 
cancer and their recurrence (Ueland, 2017). In addition, HE4 could detect epithelial ovarian 
cancer 2 to 3 months earlier than CA125 (Ueland, 2017). However, serum HE4 levels are 
changing with aging, different menopausal status, and pregnancy, which lower the specificity 
of HE4 (Moore et al., 2012).  
 The new multivariate index assays, OVA1, Overa, Risk of Ovarian Malignancy 
Algorithm (ROMA), and combining with several serum markers have been cleared by the 
FDA to assess the risk of ovarian malignancy (Bristow et al., 2013; Coleman et al., 2016; 
Moore et al., 2009; Ueland et al., 2011). The individual serum markers are CA125, HE4, 
transferrin, β-2 microglobulin, apolipoprotein A1, and transthyretin. These multivariate index 
assays significantly improved preoperative testing sensitivity compared with the single 
biomarker tests (Bristow et al., 2013). Gene mutations, such as genes of BRCA1/BRCA2, P53, 
KRAS, EGFR, and microRNAs, might be promising markers for ovarian cancer screening, 
prognosis, and prediction (Bell, 2005; Ingham et al., 2013; Milner et al., 1993; Zhang et al., 
2008). 
 
 Circulating Tumor Cells 1.6
Circulating tumor cells (CTCs) are cancer cells derive from clones in the primary tumor and 
migrate around the body via the blood circulation. Thomas Ashworth first observed CTCs in 
the blood of a man with metastatic cancer in 1869 (Ashworth, 1869). CTCs are the 
intermediates in the metastatic cascade, where a subpopulation of CTCs works as seeds and is 
responsible for the dissemination to distant sites, namely the well-known cancer metastasis, 
as shown in Figure 1.5 (Chaffer and Weinberg, 2011). As revealed by experimental studies in 
the past decade, CTCs were present in blood of patients with different types of solid 
carcinomas while absent in blood of healthy individuals and patients without malignant 
tumors (Allard et al., 2004; Cristofanilli et al., 2004; Ghossein et al., 1999; Racila et al., 
Introduction  38 
 
1998). Later, circulating tumor cells were proposed as an independent prognostic marker for 
metastasis, specifically for PFS and OS (Cohen et al., 2009; Cristofanilli et al., 2005; Danila 
et al., 2007; Giuliano et al., 2011). Enumeration of CTCs assists the prognosis of not only 
solid metastatic cancer with follow up data but also newly diagnosed cancer patients 
(Franken et al., 2012).  
A cardinal cut off of greater than or equal to five CTCs per 7.5 ml blood has been 
defined as CTC positive (Gregory et al., 2008), and it was proposed as an indicator of poor 
prognosis (Cristofanilli et al., 2005). Accordingly, those with less than 5 or no CTCs in 7.5 
ml blood are designated as CTC negative, representing good prognosis (Cristofanilli et al., 
2005). Additionally, CTCs could also predict the treatment responses in MBC, metastatic 
prostate cancer, and metastatic colorectal cancer. Therefore CTCs were also proposed as 
predictive markers (Budd et al., 2006; Cristofanilli et al., 2007; Tol et al., 2010). What is 
more, the expression profile of the hormone receptor status of CTCs could indicate the real-
time phenotype of metastasis, which could help to make appropriate treatment plans, 
especially for cancer patients at the late stages (Aktas et al., 2011; Fehm et al., 2009).  
Because of the low number of CTCs in peripheral blood, an enrichment step has to be 
done before detection (Zhe et al., 2011). The enrichment step could concentrate CTCs from 
the milieu of blood cells based on their physical features such as size, density, electric charge 
and deformability, and biological features such as surface marker or protein expression and 
invasion capacity (Alix-Panabieres and Pantel, 2014; Pantel and Alix-Panabieres, 2010). 
Currently, the gold standard of the first and only actionable test for detecting CTCs in cancer 
patients is the FDA approved CellSearchTM system. This system is based on the positive 
expression of epithelial markers epithelial cell adhesion molecule (EpCAM) or cytokeratin 8, 
18, and/or 19, and the negative expression of leukocyte CD45 on CTCs (Allard et al., 2004).     
However, it is of importance to note that a significant fraction of patients with overt 
distant metastases is negative for CTCs. This could be partly explained by EMT of CTCs, in 
which case they can be missed by enumeration techniques that exploit the expression of 
epithelial markers such as EpCAM or cytokeratin (Cristofanilli et al., 2004). The absence of 
CTCs in metastatic cancer patients gives rise to false-negative results and is the major 
drawback of the CellSearchTM system. Besides, leucocytes in the activated state have 
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epithelial markers expressed as well, thus increasing the false positive rate of CTCs (Allan 
and Keeney, 2010). Moreover, enrichment methods based on physical properties such as size 
and density have low sensitivity (Konigsberg et al., 2011; Ring et al., 2005). As a result, 
current methods for CTC detection can lead to under- or over-estimation of CTC number, so 
novel prognostic markers are highly needed. 
 
 Blood Metabolites as Tumor Markers  1.7
Cancer metabolomics studies with sample types of cell, tissue, urine, and blood have been 
reported, which have generated metabolite panels for various applications (Gunther, 2015; 
Wang et al., 2018a; Wang et al., 2016b; Xiao and Zhou, 2017). However, tissue biopsy has 
limitations of high invasive and heterogeneous, as well as the ineffectiveness in 
understanding metastatic risk, disease progression, and treatment efficiency (Marrinucci et al., 
2009). Urine samples can be easily affected by confounding factors and contaminated by 
microbiota, which makes it not the perfect sample type in biomarker study (Rodrigues et al., 
2016). The minimally invasive nature of blood samples (Crowley et al., 2013; Haber and 
Velculescu, 2014), the sensitive feature of metabolite, and the changes of metabolites in 
breast cancer initiation and progression make blood-based metabolites attractive biomarker 
candidates (Gunther, 2015). Indeed, blood metabolites associated with cancer risk have been 
studied in most cancers including breast (Fan et al., 2016b; Jasbi et al., 2019; Yuan et al., 
2018), ovarian (Fan et al., 2012; Li et al., 2017a; Zhou et al., 2010), prostate (Derezinski et 
al., 2017), colorectal (Shu et al., 2018a; Zaimenko et al., 2019), lung (Kumar et al., 2017; 
Xiang et al., 2018), pancreatic (Di Gangi et al., 2016; Kobayashi et al., 2013; Shu et al., 
2018b), and etc. 
Various studies have found promising applications for blood metabolites as detective, 
diagnosis, and prognostic markers for breast cancer. Some studies suggest the decreased 
levels of amino acids in breast cancer patients compared to healthy controls (More et al., 
2018; Shen et al., 2013; Zhou et al., 2017), and their increased levels in metastatic relative to 
early-stage breast cancer patients (Jobard et al., 2014; Oakman et al., 2011). On the contrary, 
higher levels of lipids were observed in breast cancer patients than in healthy controls (Shen 
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et al., 2013; Zhou et al., 2017), whereas lower levels of lipids were investigated in metastatic 
breast cancer than in early-stage breast cancer (Oakman et al., 2011). Apart from detection 
and prognosis, blood metabolite alterations have been linked to breast cancer treatment or 
chemotherapy response as well, which indicated the potential of metabolites as predictive 
markers (Stebbing et al., 2012; Tenori et al., 2012; Wei et al., 2013). Reports also uncovered 
the dependence of circulating metabolites profile on subgroups by examining breast cancer 
and healthy control blood from individuals with different molecular subtypes (Fan et al., 
2016b; Hart et al., 2017). However, studies about breast cancer plasma metabolites 
sometimes gave controversial results. For example, a lower serum level of glutamic acid in 
breast cancer patients was observed by Zhou et al. than in healthy controls, while Wang et al. 
showed an increased level (Wang et al., 2018b; Zhou et al., 2017). Moreover, two studies 
showed that lipids had higher amounts in the blood of metastatic breast cancer patients than 
early-stage ones (Jobard et al., 2014; Tenori et al., 2015), whereas another study indicated the 
opposite result (Oakman et al., 2011). 
Similar to other cancers and diseases, studies have found promising applications for 
blood metabolites as diagnostic, prognostic, or predictive markers in ovarian cancer, 
especially in epithelial ovarian cancer, the most common type of ovarian cancer (Turkoglu et 
al., 2016). Researchers have revealed the relationship between blood metabolites and ovarian 
cancer risk with mass spectrometry (Bachmayr-Heyda et al., 2017; Plewa et al., 2019; Yang 
et al., 2018). The pilot study to explore the relevance of plasma metabolites in ovarian cancer 
found an association between levels of plasma phosphatidylcholine, lysophosphatidylcholine, 
phosphatidylinositol, triglyceride, and sphingolipid, and ovarian cancer recurrence (Li et al., 
2017a). However, another study found some amino acids are correlated with ovarian cancer 
recurrence additional to lipids (Zhang et al., 2015). Kynurenine, acetylcarnitine, PC (42:11), 
and LPE (22:0/0:0) were selected as potential predictive markers for ovarian cancer in 
another study, with plasma samples followed up for three years (Xie et al., 2017). 
Furthermore, combining four plasma metabolites with the currently used predictive marker 
CA125 has been demonstrated to be more accurate than CA125 alone for ovarian cancer 
(Buas et al., 2016). 
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These studies suggest the possibility of using blood-based metabolic markers for the 
detection, diagnosis, and prognosis of breast cancer and ovarian cancer, irrespective of full 
understanding of the pathophysiological mechanisms. However, evidence is still limited. 
Optimized marker panels are yet to be developed and tested in large populations by high-
quality studies and further validated in prospective studies. 
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2. Aims and Objectives 
 Aims  2.1
Breast cancer is the most common cancer type in women worldwide and causes most of the 
cancer-related female deaths, which is mostly attributed to metastasis. Ovarian cancer has the 
second leading mortality rate among gynecological cancer. Detecting cancer at an early stage 
is expected to improve the survival rate. In addition, early detection and better 
prognostication of metastasis could improve patients’ outcomes and lower the high mortality 
rate. Liquid biopsy has advantages over the tissue sample because it can be accessed with 
minimally invasive procedures and monitored continuously. Cancer can cause overt 
metabolic alterations in cancer cells and the surrounding milieu. Blood metabolites have 
shown great capability as highly sensitive and informative markers in cancer, including breast 
cancer and ovarian cancer. The thesis aims to explore the potential of circulating metabolites 
as diagnostic and prognostic markers in breast cancer and ovarian cancer using a case-control 
approach. Plasma metabolites with possible diagnostic and prognostic values were identified 
in an initial discovery cohort and further tested in a validation cohort. Besides, the prognostic 
capabilities of these metabolites were compared to that of circulating tumor cells, an 
established prognostic marker for MBC patients. 
 
 Objectives  2.2
This project includes the following objectives:  
1) Identify significantly different metabolites that could distinguish:  
a. PBC patients from healthy controls 
b. MBC patients from healthy controls 
c. MBC patients from PBC patients      
d. OVCA patients from healthy controls  
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e. OVCA patients from PBC patients 
2) Identify plasma metabolites that correlate with progression-free survival and 
overall survival, which is thus of prognostic significance in MBC patients. 
3) Evaluate the potential of metabolites as putative biomarkers for early diagnosis 
and prognosis. 
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3. Materials and Methods 
 Study Samples 3.1
All studies were performed following the Declaration of Helsinki and approved by the 
Ethical Committee of Medical Faculty, University Heidelberg. In total, this project includes 
four different categories of blood samples. All subjects shared the same gender (female) and 
ethnic (Caucasian origin) background. They were provided written informed consent for the 
use of their blood samples and data.  
 
Healthy Controls - Healthy control samples from BIOMARKER Study 
The healthy controls consisted of individuals without clinically diagnosed malignancies or 
autoimmune diseases currently or historically, or current inflammation. Before blood 
withdraws, each volunteer was asked to finish a questionnaire under the supervision of study 
representatives regarding their lifestyle data. (Study Ethic number: S-175/2010, University of 
Heidelberg, Heidelberg, Germany) 
 
PBC - Primary breast cancer patients from the GENOM Study 
The PBC category included patients with sporadic and at the first diagnosis of breast cancer. 
Blood samples were collected before they underwent any therapeutic procedures, e.g., 
surgery, radiation, or systemic therapy. Histopathological and clinical-pathological features 
were determined by tumor tissues obtained from both the initial biopsy and surgical resection. 
For those who received neoadjuvant therapy, results from the former were regarded as valid 
only when the latter was not available. Histopathological and clinical pathology features of 
PBC patients were summarized in Table A1. (Study Ethic number: S-039/2008, University of 
Heidelberg, Heidelberg, Germany) 
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MBC - Metastatic breast cancer patients from CTC Study 
Breast cancer patients with one or more sites of metastasis were recruited, which were 
confirmed by radiological investigations. All MBC patients have received or were receiving 
therapy for their metastatic tumors before initial blood withdraw. Histopathological and 
clinical-pathological features of both their primary and metastatic tumors were recorded. 
Tumor progression status was radiographically monitored with around three-month intervals 
after each round of therapy. According to the RECIST guidelines, results were classified into 
complete or partial response (tumor size decrease), stable disease (tumor size neither increase 
nor decrease), or progressive disease (tumor size increase) (Eisenhauer et al., 2009). All the 
MBC patients were followed up after recruitment for up to 30 months. Histopathological 
characteristics and clinical pathology features of their metastatic tumors were summarized in 
Table A2. (Study Ethic number: S-295/2009, University of Heidelberg, Heidelberg, Germany) 
 
OVCA - Ovarian cancer patients  
The OVCA patients were recruited with the same standards as the PBC patients from the 
GENOM Study. Histopathological and clinical-pathological features of OVCA patients were 
summarized in Table A3. (Study Ethic number: S-052/2010, University of Heidelberg, 
Heidelberg, Germany). 
 
 Blood Sample Processing 3.2
Peripheral blood was drawn from all study participants into 9 ml EDTA tubes (S-Monovette®, 
Sarstedt, Nümbrecht, Germany) by nurses. Blood was centrifuged at 1300 g with a precooling 
centrifuge at 10°C for 20 min.  The resulting supernatant of the fractionated blood, i.e. 
plasma, was transferred to 2 ml vials. The fractionated blood supernatant was transferred into 
2 ml vials and was centrifuged at 15500 g with a precooling centrifuge at 10°C for 10 min, 
then a white pellet was observed. The supernatant plasma was pipetted out without touching 
the pellet and aliquoted in cryogenic vials. This step was done to ensure that the plasma was 
completely cell or cell debris free. All plasma aliquots were quickly frozen and stored at -
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80°C until the execution of metabolic analyses. The blood processing procedures for all 
sample categories are summarized in Figure 3.1. 
 
 
Figure 3.1: Blood sample pre-processing pipeline. Plasma is isolated by a two-step 
centrifugation protocol to remove cells and cell debris.  
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 CTC Detection and Enumeration 3.3
An additional 10 ml blood from MBC patients was collected into CellSaveTM tubes (Veridex, 
LLC, Raritan, NJ), of which 7.5 ml was used to enumerate intact, apoptotic, and enucleated 
CTCs. Blood samples were processed on the CellTracksTM AutoPrep system using the 
CellSearchTM circulating tumor cell kit (Veridex, LLC, Raritan, NJ), and CTC numbers were 
evaluated by the CellTracksTM AnalyserII (Veridex, LLC) (Veridex, 2010). CTC enumeration 
was done by our collaborators at the Department of Tumour Biology, University Hospital of 
Hamburg-Eppendorf. According to the number of CTCs, MBC patients were further 
classified as: 
 CTC positive (CTCpos-MBC): more than or equal to 5 intact CTCs per 7.5 ml blood. 
 CTC negative (CTCneg-MBC): less than 5 intact CTCs per 7.5 ml blood.  
 
 Metabolites Quantification by Targeted Metabolomics 3.4
3.4.1 Sample Preparation and the AbsoluteIDQ® p180 Kit 
Plasma samples were thawed on ice, centrifuged, and aliquots of 10 μL were used for 
targeted quantitative metabolite analysis. Samples were prepared and analyzed using the 
AbsoluteIDQ® p180 Kit (Biocrates Life Sciences AG, Innsbruck, Austria) in strict 
accordance with the user manual. This kit was designated to target 188 common metabolites 
in human samples, including 21 amino acids (AAs), 21 biogenic amines (BAs), 40 
acylcarnitines (ACs), 76 phosphatidylcholines (PCs), 14 lysophosphatidylcholines (lysoPCs), 
15 sphingomyelins (SMs), and the sum of hexoses (H1) (Table A4; Table 3.1). The kit is high 
throughput, reproducible, translatable, and needs a small sample volume. 
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Table 3.1: Metabolite classes in the Biocrates AbsoluteIDQ® p180 kit (adapted from the 
Biocrates product information sheet).     
Metabolite classes Numbers Biological relevances (representatives) 
Amino Acids 21 
• Immune regulation 
• Nutritional status 
• Energy homeostasis 
Biogenic Amines 21 
• Detoxification 
• Cell cycle control 
• Neurotransmission 
Acylcarnitines 40 
• Mitochondrial function 
• Fatty acid oxidation 
(Lyso-)Phosphatidylcholines 90 
• Lipoprotein structure 
• Inflammation 
Sphingolipids 15 
• Membrane composition 
• Neuroprotection 
Hexoses 1 
• Insulin resistance 
• Glycolysis and gluconeogenesis 
 
3.4.2 Metabolites Quantification    
In brief, added 10 μL of the internal standard solution, which serves as a reference for 
quantification, to each well on a filtering spot of the 96-well extraction plate. Then 10 μL of 
each plasma sample, low/medium/high-quality control (QC) samples, blank, zero samples, or 
calibration standard were added to the appropriate wells (St John-Williams et al., 2017). 
Nitrogen of a gentle stream was used to dry the plate. Samples were derivatized for AAs and 
BAs with phenyl isothiocyanate. Then with 5 mM ammonium acetate in methanol, sample 
extracts were eluted. Furthermore, sample extract dilution was performed with either kit 
running solvent for flow injection analysis tandem mass spectrometry (FIA-MS/MS) (5:1) or 
40% methanol in water for the UPLC-MS/MS analysis (2:1). Absolute quantification of AAs 
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and BAs was performed by UPLC-MS/MS analysis. ACs, SMs, and (lyso)PCs were analyzed 
by FIA-MS/MS. Peak integration, calibration, and concentration calculations of the UPLC-
MS/MS data were done by TargetLynxTM (Waters Corporation). Then Biocrates’ MetIDQTM 
software was used to analyze both the UPLC-MS/MS data processed by TargetLynxTM and 
the data generated from FIA-MS/MS. All metabolite concentrations are reported in 
micromolar. 
 
3.4.3 Quality Controls and Technical Validation 
All samples were randomized and evenly distributed on seven kit plates. On each plate, one 
low-level QC, five medium levels QC, and one high-level QC samples were measured. To 
prove the validity of the run, and to verify the authentic performance of the applied 
quantitative procedure, technical validation of each analyzed kit plate was done automatically. 
MetIDQTM software was used to perform inter-plate technical validation (St John-Williams et 
al., 2017). All measured plates passed the technical validation, which confirmed the high 
quality and accuracy of the quantitative metabolomics data obtained. In order to minimize 
batch effects, normalization using medium level QC measurement was applied. 
Normalization procedure was performed by MetIDQTM software too. 
 
 Statistical Analysis 3.5
For each sample category, two independent study cohorts were included, the discovery cohort 
of 314 individuals included 100 MBC, 80 PBC, and 34 OVCA patients, and 100 healthy 
controls to identify potential candidate metabolites, while the validation cohort of 237 
samples consisted of 78 MBC, 109 PBC, and 35 OVCA patients, and 50 healthy controls. 
Among the 80 PBC samples in the discovery cohort, three with confirmed late-stage breast 
cancer and one with breast angiosarcoma, so these four samples were removed from the 
downstream analysis. Among the 78 MBC patients in the validation cohort, CTC status 
information was lacking for two, and they were excluded when identifying prognostic 
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markers for MBC. Additionally, four samples did not feature any FIGO staging information 
within the 35 OVCA samples in the validation cohort. The types and number of samples were 
listed in Table 3.2. All statistical analysis was performed with R3.5.1 (Team, 2015).   
 
Table 3.2: Overall of the type and number of samples used in this thesis work.    
 
 
3.5.1 Quality Control 
Metabolites were excluded when the percentage of concentration values, missing or below 
the limit of detection (LOD), was higher than 20%, and when batch coefficients of variation 
were larger than 0.3. Five healthy and five OVCA plasma samples from the discovery cohort 
were measured in triplicates to test the reliability of the mass spectrometry generated 
metabolite data. Metabolite SM C22:3 had coefficients of variation larger than 0.3 and, 
therefore, it was excluded from the following statistical analysis (Figure A1). After filtering 
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out metabolites with percentages of LOD or missing values higher than 20% (n = 50), the 
remaining values that below LOD or missing were replaced by imputed values between LOD 
and LOD/2 following equal distribution. At last, the remaining 138 unique and variably 
expressed metabolites were used for subsequent comparisons. All metabolite concentration 
values were log2 transformed and then normalized by the metabolite-wise batch 
standardization. 
 
3.5.2 The Difference in Metabolites between Groups 
Age was the only clinical characteristic available in all study groups and was unequally 
distributed among different groups, especially in the validation cohort (Figure A2). Human 
serum metabolic profiles are age-dependent (Yu et al., 2012), which was also verified in our 
study (Figure A3). Therefore, age was always adjusted in the univariate logistic regression 
analysis, which aimed to identify significantly altered metabolites between study groups or 
subgroups in the discovery cohort. The resulting p-values were adjusted for multiple testing 
by controlling for the false discovery rate (FDR; Benjamini-Hochberg method). All statistical 
tests were two-sided; FDR below 0.05 were regarded as statistically significant.  
The identified metabolites were further validated by age-adjusted univariate logistic 
regression analysis in an independent validation cohort. Only metabolites with FDR less than 
0.05 were chosen for downstream analysis. To compute the least redundant and most 
informative panel of metabolites that could discriminate different groups, penalized LASSO 
logistic regression models (ten-fold cross-validation to tune penalty parameter) were built 
(Tibshirani, 1996). This process was implemented in the R package “glmnet”. The 
corresponding area under the curve (AUC) was calculated for each multivariable model, as 
well as the sensitivities at predefined specificities with corresponding 95% confidence 
intervals (CIs). The performance of each metabolite was evaluated by using a ten-fold cross-
validated receiver operating characteristic (ROC) curve based on the logistic regression 
model.   
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3.5.3 Correlation between Variables 
Relationships between investigated metabolites were evaluated by partial Spearman 
correlation, which could adjust the remaining variables when calculating the correlation 
between any two metabolites. Relationships between metabolite concentrations and CTC 
numbers were analyzed by Spearman rank correlation.   
 
3.5.4 Correlation with Survival 
Period (in months) from blood withdrawn to the progression of the disease or last radiological 
examination was defined as PFS, while to death or last visit was regarded as OS. Each 
metabolite was dichotomized as the lowest quartile and the residual quartiles based on its 
concentration. Then the log-rank test was applied on the stratified data to compare the 
probability of survival between these two groups. Kaplan-Meier curve was constructed at the 
same time to demonstrate the relationship between individual metabolite levels and survival 
time. Metabolites that showed significant associations with survival in the univariate log-rank 
tests were imported into a multivariate LASSO cox model. Relevant metabolite variables 
were selected automatically with the LASSO penalty (ten-fold cross-validation to tune the 
penalty parameter) (Tibshirani, 1996).  
 
Comparison of survival models 
Survival models, including metabolite variables alone, CTC status alone, or metabolite 
variables with CTC status, were built. The 0.632+ bootstrap was used to evaluate the 
prognostic values of models by estimating the prediction error of LASSO cox models. The 
resulting values were summarized as the integrated prediction error (IPE) curve up to 30 
months (Gerds and Schumacher, 2007). Then IPEs of the models were compared to 
determine the best model. The lower of the IPE value of a model indicates the higher model 
accurate, which fits the data better. 
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3.5.5 Correlation with Clinical Characteristics 
When calculating the relationships between metabolite levels and clinical characteristics, 
different tests were used according to the data type. For categorical and binary data, 
Wilcoxon rank-sum tests were used. Spearman correlation permutation tests fitted the 
quantitative and continuous data better, while Jonckheere-Terpstra tests were the best for 
ordinal data. For clinical features that are distributed differently between CTCpos-MBC and 
CTCneg-MBC sub-groups, logistic regression analysis with covariates adjusted was done. In 
this way, authentic significance contributed by metabolites in differentiating between groups 
or the actual association between metabolites and survival could be evaluated.  
 
 Pathway Analysis 3.6
Associated metabolic pathways that these significantly different metabolites between PBC 
and healthy controls participated in were enriched by MetaboAnalyst 3.0 (Xia et al., 2015). 
This online software MetaboAnalyst 3.0 imported the concentration data of metabolites, and 
the standard metabolite names were human metabolome database (HMDB) IDs. The pathway 
library of “Homo sapiens” was selected. Pathway analysis algorithm of “Global test” was 
used for enrichment analysis, while the algorithm of “Out-degree Centrality” was used for 
topology analysis. 
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4. Results 
 Early Detective Value of Plasma Metabolites in PBC 4.1
Patients  
4.1.1 Global plasma metabolite profiles of PBC patients and healthy controls   
Estrogen receptor (ER) status and age were not equally distributed between discovery and 
validation cohorts, with the p-values for chi-square test were 0.047 and 0.001, respectively 
(Table A2). Fold changes (FCs) were calculated to show the distribution trend of metabolites 
and univariate logistic regression models were constructed to distinguish statistically different 
metabolites (p < 0.05) between PBC patients and healthy controls, with age was adjusted for 
its effect. Resulting p-values were adjusted for multiple comparisons. In the discovery cohort, 
between PBC patients and healthy controls, a total of 37 metabolites were significantly 
different, with six up-regulated metabolites and 31 down-regulated metabolites observed in 
PBC patients. In the validation cohort, 24 metabolites were significantly different, of which 
21 metabolites were found to be down-regulated while three metabolites up-regulated in PBC 
patients (Figure 4.1) (Yuan et al., 2018). 
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Figure 4.1: The volcano plot shows the comparison between PBC patients and healthy 
controls. The Y-axis represents -log10 (FDR: adjusted p-value with Benjamini-Hochberg), 
while the horizontal axis represents log2 (fold change: PBC patient versus healthy control), 
each spot symbolizes one metabolite. The dotted horizontal purple line highlights the 
statistical significance threshold (FDR < 0.05). Round spots represent metabolites in the 
discovery cohort, while triangular spots represent metabolites in the validation cohort. 
Metabolites that are not significantly altered are shown in grey, while significant metabolites 
are shown in red. Those that are prominent in both cohorts are shown in cyan and marked 
with text. 
 
Among these significantly altered metabolites, 18 metabolites were present in both 
discovery and validation cohorts (Table 4.1). Compared to healthy controls, 13 amino acids, 
two biogenic amines, and one acylcarnitine of downregulation, two acylcarnitines of 
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upregulation were detected in PBC patients. A heatmap visualized sample clustering based on 
the expression levels of these 18 metabolites with Euclidean distance metrics showed 
different clustering patterns of up-regulated and down-regulated metabolites (Figure 4.2) 
(Yuan et al., 2018). 
 
Table 4.1: List of significantly different levels of metabolite between PBC patients and 
healthy controls in the discovery and validation cohort.  
Metabolites (18) 
Discovery cohort Validation cohort 
p-value FDR FC p-value FDR FC 
Ala ↓ 4,59E-04 3,33E-03 -1,13 1,59E-03 1,45E-02 -1,12 
Asn ↓ 2,45E-04 2,16E-03 -1,16 7,46E-05 2,48E-03 -1,21 
Glu ↓ 1,03E-03 6,45E-03 -1,33 7,74E-04 9,41E-03 -1,31 
His ↓ 1,60E-04 1,83E-03 -1,11 3,14E-03 2,70E-02 -1,11 
Leu ↓ 3,99E-03 1,67E-02 -1,14 5,10E-03 3,72E-02 -1,13 
Lys ↓ 1,52E-04 1,83E-03 -1,15 1,48E-03 1,44E-02 -1,13 
Met ↓ 2,67E-03 1,27E-02 -1,17 8,48E-05 2,48E-03 -1,20 
Orn ↓ 6,26E-06 1,73E-04 -1,24 1,20E-05 8,79E-04 -1,27 
Phe ↓ 2,15E-03 1,10E-02 -1,10 6,95E-03 4,23E-02 -1,09 
Thr ↓ 2,51E-04 2,16E-03 -1,18 6,72E-03 4,23E-02 -1,18 
Trp ↓ 2,04E-06 1,22E-04 -1,21 1,83E-05 8,91E-04 -1,20 
Tyr ↓ 2,59E-05 5,95E-04 -1,21 6,04E-03 4,20E-02 -1,11 
Val ↓ 3,26E-04 2,50E-03 -1,12 6,79E-03 4,23E-02 -1,08 
Kynurenine ↓  2,79E-04 2,27E-03 -1,22 1,05E-03 1,10E-02 -1,17 
Met-SO ↓ 2,65E-06 1,22E-04 -1,46 1,27E-04 2,65E-03 -1,31 
C3 ↓ 4,18E-06 1,44E-04 -1,31 7,59E-04 9,41E-03 -1,19 
C2 ↑ 1,56E-07 2,16E-05 1,46 3,06E-04 4,47E-03 1,41 
C14:1 ↑ 2,40E-04 2,16E-03 1,19 2,91E-04 4,47E-03 1,35 
Note: The arrows indicate the relative increase/decrease of metabolite levels in PBC patients 
compared to healthy controls. p-values were adjusted for Benjamini-Hochberg correction. 
The criteria for selecting significantly altered metabolites were: FDR <0.05.  
Results   58 
 
 
Figure 4.2: Supervised hierarchical complete linkage clustering with Euclidean distance 
metric, depending on the 18 significantly different metabolites between PBC patients and 
healthy controls.  
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4.1.2 A panel of metabolites associated with breast cancer early diagnosis and 
detection 
The diagnostic potential of metabolite panel was assessed through more advanced statistical 
tools. A multi-parameter ROC curve that established through a penalized LASSO logistic 
regression model (adjusting penalty parameters through 10-fold cross-validation) was used to 
build the least redundant and most informative metabolite panel. This panel was able to 
distinguish between PBC patients and healthy controls. The discovery cohort was used to 
build a robust statistical model, while the validation cohort was used for model selection and 
final classification model testing. The corresponding AUC was calculated for the LASSO 
logistic regression model. Finally, a multivariate model containing seven metabolites (Glu, 
Orn, Thr, Trp, Met-SO, C2, C3) was predicted, which produced high discrimination accuracy 
with AUCs of 0.87 (95% CI: 0.81 ~ 0.92) and 0.80 (95% CI: 0.71 ~ 0.87) for the discovery 
and validation cohorts, respectively (Figure 4.3) (Yuan et al., 2018). 
The leave-one-out cross-validated ROC curve built with the logistic regression model 
revealed that each metabolite in the panel could distinguish PBC patients from healthy 
controls (Figure 4.4). However, the combination of these seven metabolites performed better 
than individual metabolites (Figure 4.3). The AUC of each metabolite in the validation group 
was as follows: Glu (AUC 0.66), Orn (AUC 0.68), Thr (AUC 0.66), Trp (AUC 0.73), Met-
SO (AUC 0.68), C2 (AUC 0.72), and C3 (AUC 0.64) (Yuan et al., 2018). 
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Figure 4.3: Multi-parameter ROC classifier curves for distinguishing between PBC patients 
and healthy controls. The multi-parameter panel with seven variables selected by the 
penalized LASSO logistic regression model shows the best performance for the discovery 
and validation cohorts. The solid colored line typifies the discriminative power of the 
classifier and corresponding AUC value and 95% CI are displayed. ROC curve is colored 
according to cutoff values, and scale is shown on the right side of the graph. The x-axis and 
the y-axis represent the false positive rate (1-specificity) and the true positive rate 
(sensitivity), respectively. The diagonal dashed gray line means no separation ability, i.e. 
random classification. 
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Figure 4.4: Univariate ROC curves for leave-one-out cross-validated logistic regression 
models based on the ability of individual metabolites to distinguish between PBC patients 
and healthy controls. The ROC curves for the discovery and validation cohorts are displayed 
in red and blue lines, respectively. The diagonal gray line means no separation ability, i.e. 
random classification. 
 
Results   62 
 
In this thesis project, most of the PBC patients were at stage I or stage II (71 of 80 in the 
discovery cohort and 99 of 109 in the validation cohort). The logistic regression model, with 
only stage I and II breast cancer patients, was established to validate the potential 
classification functions of these seven metabolites further. The multi-parameter ROC curve 
had an AUC of 0.80 (95% CI: 0.71 ~ 0.87), which was equivalent to the AUC of all PBC 
patients. AUCs of individual metabolites from stage I and II breast cancer patients were 
similar to those from all PBC patients. The metabolite panel had better breast cancer 
detection capabilities than each metabolite in the panel as well (Yuan et al., 2018). 
 
4.1.3 Pathway analysis 
With metabolite concentration data, pathway enrichment analysis was performed to compare 
the metabolism of PBC patients to healthy controls. As a result, significant differences were 
observed between the two groups (Figure 4.5). In total, a list of 28 metabolic pathways was 
connected with significantly differentiated metabolites, among which 12 pathways were 
significant (p < 0.05). These pathways mostly involve acid metabolism, aminoacyl-tRNA 
biosynthesis, and nitrogen metabolism (Yuan et al., 2018). These pathways mostly involve 
acid metabolism, aminoacyl-tRNA biosynthesis, and nitrogen metabolism (Yuan et al., 2018). 
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Figure 4.5: All matched pathways, according to the p-values from pathway enrichment 
analysis (y-axis) and pathway impact values obtained from pathway topology analysis (x-
axis), for metabolites that could distinguish PBC patients from healthy controls. The color 
and size of each circle represent the p-value and pathway impact value, respectively. Pathway 
analysis was performed using the MetaboAnalyst 3.0 online tool. 
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 Diagnostic Value of Plasma Metabolites in MBC Patients  4.2
4.2.1 Plasma metabolite profiles of MBC, PBC patients, and healthy controls 
In the discovery cohort, plasma samples consist of 100 MBC patients (44 CTC-positive and 
56 CTC-negative), 76 PBC patients, and 100 healthy controls. In CTC-positive MBC patients, 
82 metabolites were found to be differentially expressed in comparison to healthy controls, 
whereas, only 17 metabolites were differentially expressed in CTC-negative MBC patients 
when compared to healthy controls. Similar results were obtained when comparing MBC to 
PBC patients. Indeed, 62 significantly different metabolite levels were observed after 
comparing CTC-positive MBC to PBC patients, while only 19 metabolite levels were 
significantly different between CTC-positive MBC and PBC patients.      
Significant differentially expressed metabolites identified in the discovery cohort were 
further tested in an expanded independent sample set with 76 MBC patients (21 CTC-positive, 
55 CTC-negative), 109 PBC patients, and 50 healthy controls. Univariate logistic regression 
analysis was used to validate the metabolites that could separate different groups. We 
confirmed 19 metabolite levels (five increased and 14 decreased) for CTC-positive MBC 
patients, and 12 metabolite levels (seven elevated and five reduced) for CTC-negative MBC 
patients were significantly different from healthy controls (Table 4.2). Likewise, 25 
metabolite levels (six increased and 19 decreased) for CTC-positive patients and nine 
metabolite levels (seven elevated and two reduced) for CTC-negative patients were found to 
be significantly different from PBC patients (Table 4.3). More metabolites were identified for 
patients with CTC-positive MBC than CTC-negative MBC in comparison to healthy controls 
or PBC patients. So the differences between CTC-positive MBC patients and controls or PBC 
patients were larger than that for CTC-negative MBC patients (Figure 4.6). These 35 
metabolites, including amino acids, biogenic amines, short- and long-chain acylcarnitines, 
lysophosphatidylcholines, and phosphatidylcholines, differed significantly between MBC 
patients and PBC patients or healthy controls.  
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Table 4.2: Metabolite levels are significantly different between CTC-positive or CTC-negative 
MBC patients and healthy controls.  
CTC-positive MBC vs. Control CTC-negative MBC vs. Control 
Metabolites  FC FDR AUC Metabolites  FC FDR AUC 
Asn ↓ -1.25 2.71E-02 0.71 Asn ↓ -1.24 7.26E-04 0.72 
Glu ↑ 1.69 1.29E-02 0.82 Glu ↑ 1.60 7.26E-04 0.72 
His ↓ -1.16 3.06E-02 0.79 His ↓ -1.16 9.21E-04 0.73 
Trp ↓ -1.17 3.92E-02 0.75 Thr ↓ -1.17 1.73E-02 0.69 
C4:0 ↑ 1.99 9.59E-03 0.79 Trp ↓ -1.24 2.44E-04 0.71 
C16:0 ↑ 1.29 3.05E-02 0.77 C2:0 ↑ 1.41 9.21E-04 0.68 
C18:1 ↑ 1.29 4.19E-02 0.80 C16:0 ↑ 1.41 3.28E-04 0.74 
lysoPC a C18:2 ↓ -1.65 9.56E-03 0.88 C18:0 ↑ 1.34 9.65E-04 0.66 
PC aa C40:6 ↑ 1.52 9.59E-03 0.74 C18:1 ↑ 1.50 2.44E-04 0.78 
PC ae C34:2 ↓ -1.25 3.42E-02 0.75 C18:2 ↑ 1.35 9.21E-04 0.71 
PC ae C34:3 ↓ -1.43 9.59E-03 0.76 lysoPC a C18:2 ↓ -1.33 9.21E-04 0.72 
PC ae C36:3 ↓ -1.32 9.59E-03 0.78 PC aa C40:6 ↑ 1.29 1.91E-03 0.68 
PC ae C40:4 ↓ -1.25 1.41E-02 0.68 
    
PC ae C42:3 ↓ -1.29 1.29E-02 0.83 
    
PC ae C42:4 ↓ -1.53 2.81E-03 0.77 
    
PC ae C44:3 ↓ -1.25 2.29E-02 0.77 
    
PC ae C44:4 ↓ -1.51 2.81E-03 0.80 
    
PC ae C44:5 ↓ -1.51 2.81E-03 0.72 
    
PC ae C44:6 ↓ -1.36 9.56E-03 0.69 
    
Note: Results of fold change (FC), univariate logistic regression with corresponding false 
discovery rate (FDR), and ten-fold cross-validated area under the curve (AUC) estimate for 
significantly different metabolites in both cohorts are shown. 
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Table 4.3: Metabolite levels are significantly different between CTC-positive or CTC-negative 
MBC and PBC patients.  
CTC-positive MBC vs. PBC CTC-negative MBC vs. PBC 
Metabolites FC FDR AUC Metabolites FC FDR AUC 
Arg ↓ -1.25 2.03E-02 0.80 Arg ↓ -1.17 1.67E-02 0.67 
Glu ↑ 2.22 1.58E-04 0.90 Glu ↑ 2.10 1.77E-07 0.85 
Orn ↑ 1.29 1.81E-03 0.70 Orn ↑ 1.49 2.57E-08 0.83 
Kynurenine ↑ 1.28 9.84E-03 0.66 Kynurenine ↑ 1.25 1.63E-03 0.68 
Met-SO ↑ 1.36 1.37E-02 0.68 Met-SO ↑ 1.36 6.11E-04 0.69 
C4:0 ↑ 2.19 4.23E-04 0.85 Spermidine ↑ 1.13 1.67E-02 0.63 
lysoPC a C18:2 ↓ -1.49 2.07E-03 0.83 C4:0 ↑ 1.49 3.20E-03 0.69 
lysoPC a C20:3 ↓ -1.31 1.37E-02 0.69 C18:2 ↑ 1.33 1.91E-04 0.69 
lysoPC a C20:4 ↓ -1.22 3.52E-02 0.71 lysoPC a C18:2 ↓ -1.20 8.31E-03 0.64 
PC aa C40:6 ↑ 1.43 1.11E-03 0.73 
    PC aa C42:1 ↓ -1.21 3.52E-02 0.67 
    PC ae C34:2 ↓ -1.28 4.58E-03 0.73 
    PC ae C34:3 ↓ -1.38 1.63E-03 0.73 
    PC ae C36:3 ↓ -1.37 4.23E-04 0.76 
    PC ae C40:1 ↓ -1.19 1.35E-02 0.75 
    PC ae C40:3 ↓ -1.19 7.75E-03 0.68 
    PC ae C40:4 ↓ -1.33 4.18E-04 0.71 
    PC ae C42:1 ↓ -1.19 7.75E-03 0.73 
    PC ae C42:3 ↓ -1.31 2.07E-03 0.81 
    PC ae C42:4 ↓ -1.62 1.15E-04 0.81 
    PC ae C42:5 ↓ -1.42 1.45E-04 0.75 
    PC ae C44:3 ↓ -1.31 2.72E-03 0.78 
    PC ae C44:4 ↓ -1.61 1.15E-04 0.82 
    PC ae C44:5 ↓ -1.64 1.15E-04 0.77 
    PC ae C44:6 ↓ -1.46 4.23E-04 0.73 
     
 
Results   67 
 
 
Figure 4.6: Supervised hierarchical complete linkage clustering with Euclidean distance 
metric, depending on the 35 significantly different metabolites between MBC patients and 
PBC patients or healthy controls.  
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4.2.2 Plasma metabolite panels associated with metastatic breast cancer early 
detection 
A multivariable penalized LASSO logistic regression model (ten-fold cross-validated) 
comprising six metabolites (His, C4:0, C18:1, lysoPC a C18:2, PC aa C40:6, and PC ae 
C42:3) was predicted. It yielded a high discriminatory accuracy with an AUC of 0.92 (95% 
CI: 0.86 ~ 0.99) for CTC-positive MBC patients versus healthy controls. For CTC-negative 
MBC patients versus healthy controls, the predicted model consisting of 11 metabolites (Asn, 
Glu, His, Thr, Trp, C16:0, C18:0, C18:1, C18:2, lysoPC a C18:2, and PC aa C40:6) had the 
best distinguishing performance with an AUC of 0.89 (95% CI: 0.83 ~ 0.95). Another 
multivariable model was built to compare CTC-positive MBC and PBC patients, which 
contained 15 selected metabolites (Arg, Glu, Orn, C4:0, lysoPC a C18:2, lysoPC a C20:4, PC 
aa C40:6, PC aa C42:1, PC ae C34:2, PC ae C34:3, PC ae C36:3, PC ae C42:1, PC ae C42:3, 
PC ae C42:5, and PC ae C44:4) and generated an AUC of 0.95 (95% CI: 0.9 ~ 1.0). Though 
individual metabolite could not distinguish CTC-negative MBC patients from PBC patients 
with high accuracy, the model with a combination of seven metabolites (Arg, Glu, Orn, Met-
SO, spermidine, C4:0, and lysoPC a C18:2) predicted an appreciable AUC of 0.90 (95% CI: 
0.86 ~ 0.95) (Figure 4.7). 
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Figure 4.7: ROC curves for multivariable panels based on penalized LASSO logistic 
regression models to discriminate MBC patients from PBC patients or healthy controls. CTC-
positive MBC patients versus control: His, C4:0, C18:1, lysoPC a C18:2, PC aa C40:6, and 
PC ae C42:3; CTC-negative MBC patients versus control: Asn, Glu, His, Thr, Trp, C16:0, 
C18:0, C18:1, C18:2, lysoPC a C18:2, and PC aa C40:6; CTC-positive MBC versus PBC 
patients: Arg, Glu, Orn, C4:0, lysoPC a C18:2, lysoPC a C20:4, PC aa C40:6, PC aa C42:1, 
PC ae C34:2, PC ae C34:3, PC ae C36:3, PC ae C42:1, PC ae C42:3, PC ae C42:5, and PC ae 
C44:4; CTC-negative MBC versus PBC patients: Arg, Glu, Orn, Met-SO, spermidine, C4:0, 
and lysoPC a C18:2.  
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Figure 4.8: Distribution of the LASSO selected metabolite concentrations in CTC-positive 
MBC, CTC-negative MBC, PBC patients, and healthy controls. Box plots of metabolites are 
represented as the logarithm of concentration to the base 2 values. 
 
Boxplots for the 25 metabolites selected by the four multivariate penalized LASSO 
logistic regression models were constructed to show the distributions of metabolite 
concentrations in each group (Figure 4.8). Ten-fold cross-validated univariate ROC analysis 
for each candidate metabolite in the set could predict the ability to distinguish CTC-positive 
or CTC-negative MBC patients from PBC patients or healthy controls. Even though 
individual metabolites could distinguish different groups by themselves, multivariable models 
with selected panels performed better (Figure 4.7; Figure 4.9). Among these 25 metabolites, 
glutamate showed the best ability to discriminate different groups (Table 4.2; Table 4.3; 
Figure 4.9). Remarkably, ornithine and Met-SO could differentiate MBC patients from PBC 
patients better than MBC patients from healthy controls (Figure 4.9). 
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Figure 4.9: Ten-fold cross-validated ROC curves based on univariate logistic regression models 
for the selected individual metabolites. The ROC curves for CTC-positive MBC patients versus 
healthy controls, CTC-negative MBC patients versus healthy controls, CTC-positive MBC versus 
PBC patients, and CTC-negative MBC versus PBC patients are displayed in red solid, blue 
dashed, purple dotted, and black dot-dashed lines, respectively. The diagonal gray line means no 
separation ability, i.e. random classification. 
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 Prognostic Value of Plasma Metabolites in MBC Patients  4.3
4.3.1 Plasma metabolites correlated with PFS and OS 
Survival data were available for all MBC patients in both discovery and validation cohorts. 
The log-rank test was employed to identify metabolites that could predict PFS and OS. Each 
metabolite was categorized into two classes according to its concentration value: the lowest 
quartile and the residual quartiles. In the discovery cohort, 16 and 51 metabolites were 
significantly correlated with PFS and OS (p < 0.05), respectively. These metabolites were 
further tested in the validation cohort. Ultimately, four metabolites, kynurenine, PC aa C36:3, 
PC ae C36:1, and PC ae C38:3, were correlated with PFS significantly. Here, p-values were 
not adjusted for multiple testing. Higher levels of these metabolites were found to be 
associated with higher probabilities of PFS (Table 4.4; Figure 4.10A). Twelve metabolites, 
lysoPC a C18:1, lysoPC a C20:3, lysoPC a C20:4, PC aa C36:3, PC aa C36:4, PC aa C38:5, 
PC ae C36:1, PC ae C38:3, PC ae C38:4, PC ae C40:2, SM C18:1, and SM (OH) C22:2, were 
also positively related to OS significantly (Table 4.4; Figure 4.10B). 
Table 4.4: Associations between plasma metabolites or CTC counts and PFS and OS 
assessed by the log-rank model.  
Metabolites PFS OS 
Kynurenine 3.88E-04 3.94E-01 
lysoPC a C18:1 3.08E-01 1.18E-03 
lysoPC a C20:3 7.78E-02 6.63E-05 
lysoPC a C20:4 7.47E-01 5.09E-04 
PC aa C36:3 2.98E-03 1.81E-07 
PC aa C36:4 2.20E-01 1.15E-05 
PC aa C38:5 2.30E-01 9.59E-05 
PC ae C36:1 2.77E-03 6.33E-04 
PC ae C38:3 1.79E-04 1.12E-08 
PC ae C38:4 7.98E-02 1.30E-03 
PC ae C40:2 4.35E-01 5.40E-03 
SM C18:1 1.73E-01 1.23E-06 
SM (OH) C22:2 3.30E-01 6.28E-05 
CTC 3.05E-02 6.37E-10 
Note: significant results are in bold. 
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Figure 4.10: Kaplan-Meier curves of the CTC status and metabolites that significantly 
correlated with progression-free survival (PFS, A) and overall survival (OS, B). Metabolite 
levels were stratified according to their concentrations as the lowest quartile (“Low”) and 
residual quartiles (“High”). CTCs were stratified as CTC-positive and CTC-negative.  
 
4.3.2 Correlations of plasma metabolites with CTC counts 
For these 12 metabolites that related to OS, spearman correlation analysis was performed to 
assess the correlations between metabolite concentrations and CTC counts. Results revealed 
that kynurenine, PC ae C36:1, PC ae C40:2, and SM C18:1 were not significantly correlated 
with CTC counts, while the other metabolites were negatively correlated with CTC counts 
significantly. The lower metabolite concentrations, the higher CTC numbers (Figure 4.11).    
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Figure 4.11: Spearman rank correlation of metabolite concentrations and CTC numbers. 
Metabolites significantly associated with CTC counts are marked with texts of correlation 
coefficients. The green dots represent positive correlations, while red dots indicate negative 
correlations. 
 
4.3.3 Evaluation and comparison of putative prognostic models 
The LASSO cox model predicted that combination of PC ae C36:1 and PC ae C38:3 for PFS 
(IPE = 5.669 compared to IPE0 = 5.689 for the null model without covariate information) and 
combination of lysoPC a C20:3, lysoPC a C20:4, PC aa C38:5, PC ae C38:3, and SM (OH) 
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C22:2 for OS (IPE = 5.795 compared to IPE0 = 6.130 for the null model without covariate 
information) were the best-fitting multivariate models, as shown in Table 4.5. When CTCs 
were introduced into these multivariable metabolite models, the IPEs were somewhat lower 
but essentially unchanged (PFS: 5.610, OS: 5.254; Figure 4.12). For PFS, PC ae C36:1 
outperformed the multivariable model (IPE = 5.617), while lysoPC a C20:3 outperformed the 
multivariable for OS (IPE = 5.722). In comparison to CTCs (IPE of 5.628 for PFS and 5.268 
for OS), PC ae C36:1 performed slightly better for PFS, but lysoPC a C20:3 performed worse 
for OS. However, combinations of PC ae C36:1 with CTCs and lysoPC a C20:3 with CTCs 
showed better prediction accuracies than CTCs alone for PFS (IPE = 5.535) and OS (IPE = 
5.082), respectively (Figure 4.13).  
 
 
Figure 4.12: Integrated prediction error (IPE) curves up to 30 months for the null model 
(Kaplan-Meier model without any covariate information), CTC, multivariate metabolite 
model, and metabolite model + CTC for PFS and OS. The number of individuals at risk at 
different time points is indicated along the x-axis. The y-axis represents prediction errors of 
the LASSO cox model. 
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Figure 4.13: Integrated prediction error (IPE) curves for PFS (A) and OS (B). The curves 
were up to 30 months for the null model (Kaplan-Meier model without any covariate 
information), CTCs, PC ae C36:1 (PFS)/lysoPC a C20:3 (OS), and PC ae C36:1 
(PFS)/lysoPC a C20:3 (OS) + CTCs. The number of individuals at risk at different time 
points is indicated along the x-axis. The y-axis represents prediction errors of the LASSO cox 
model. 
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Table 4.5: Different LASSO cox models for PFS and OS in MBC patients, corresponding 
integrated prediction errors (IPE) were shown.  
Type Model 
PFS OS 
Variables  IPE Variables  IPE 
O
n
e-
m
et
ab
o
li
te
 Null model  None  5.689 None 6.130 
Metabolite 
model 
PC ae C36:1 5.617 lysoPC a C20:3 5.722 
CTC model CTC status  5.628 CTC status 5.268 
Metabolite + 
CTC model 
PC ae C36:1, 
CTC status 
5.535 lysoPC a C20:3, CTC status 5.082 
M
u
lt
i-
m
et
ab
o
li
te
s 
Null model  None 5.689 None 6.130 
Metabolites 
model 
PC ae C36:1, PC 
ae C38:3 
5.669 
lysoPC a C20:3, lysoPC a 
C20:4, PC aa C38:5, PC ae 
C38:3, SM (OH) C22:2 
5.795 
CTC model CTC status 5.628 CTC status 5.268 
Metabolites + 
CTC model 
PC ae C36:1, PC 
ae C38:3, CTC 
status  
5.610 
lysoPC a C20:3, lysoPC a 
C20:4, PC aa C38:5, PC ae 
C38:3, SM (OH) C22:2, CTC 
status 
5.254 
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 Diagnostic Value of Plasma Metabolites in OVCA 4.4
Patients  
4.4.1 Plasma metabolite profiles of OVCA, PBC patients, and healthy 
controls 
With the remaining 138 metabolites after removing outliers, principal component analysis 
(PCA) was performed for OVCA patients and healthy controls in the discovery and 
validation cohorts. As shown in Figure 4.14, the separation of these two groups was based on 
the first principal component, and the separation of samples within the groups was mostly 
depending on the second principal component. The variance of ovarian cancer patients was 
generally higher than healthy controls, which may be related to the heterogeneous nature of 
ovarian cancers. The highest contribution to the overall variance originates from 
phosphatidylcholines and acylcarnitines. 
 
 
Figure 4.14: PCA scoring plot on the metabolite dataset of ovarian cancer patients and 
healthy controls for the discovery cohort (A) and validation cohort (B) with outliers excluded, 
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95% confidence ellipses are drawn for each group. Round red spots represent samples from 
healthy controls, while triangular aqua spots represent samples from ovarian cancer. 
 
The data set of the discovery cohort consisted of 34 OVCA patients, 80 PBC patients, 
and 100 healthy controls. A total of 94 metabolites were differentially expressed between 
OVCA patients and healthy controls (FDR < 0.05). The data set for validating the potential 
metabolites consisted of 35 OVCA patients, 109 BC patients, and 50 healthy controls. 
Among these significant differentially expressed metabolites identified in the discovery 
cohort, 71 were verified independently to separate OVCA samples from healthy controls, 
including seven amino acids, four acylcarnitines, five lysophosphatidylcholines, 54 
phosphatidylcholines, and one sphingomyelin. Except for the increased levels of Glu, C2, 
C18:1, and C18:2 in ovarian cancer patients relative to healthy controls, all the other 
identified differentially expressed metabolites were down-regulated. 
 
4.4.2 A panel of plasma metabolites associated with OVCA diagnosis 
The resulting 71 features were reduced by LASSO regression analysis as described in the 
Methods. Videlicet, models were trained on the discovery cohort with ten-fold cross-
validation, which generated an optimal parameterized model consisted of a subset of seven 
metabolites: His, Trp, C18:1, lysoPC a C18:2, PC aa C32:2, PC aa C34:4, and PC ae C34:3. 
Following training, this panel of metabolites was tested on an independent validation dataset 
consisted of 35 OVCA patients, 109 PBC patients, and 50 healthy controls. The performance 
of this classifier was as high as AUC = 0.95 (95% CI: 0.89 ~ 1.00) (Figure 4.15, left). 
FIGO stages I and II are designated as early-stage OVCA, while stages III and IV are 
designated as late-stage OVCA. Correspondingly, the discovery cohort included three early-
stage and 31 late-stage OVCA samples, while the validation cohort contained ten early-stage 
and 21 late-stage OVCA samples. There were only ten and three early-stage samples in the 
discovery and validation cohort, respectively. The model with seven metabolites that could 
discriminate OVCA patients from healthy controls achieved an AUC of 0.87 (95% CI: 0.76 ~ 
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0.97) for early-stage OVCA samples (Figure 4.15, middle) and an AUC of 0.96 (95% CI: 
0.92 ~ 1.00) for late-stage OVCA samples to differentiate from healthy controls (Figure 4.15, 
right). 
 
 
Figure 4.15: ROC curves for a seven metabolites panel to distinguish between OVCA 
patients and healthy controls (left), early-stage OVCA patients and healthy controls (middle), 
late-stage OVCA patients and healthy controls (right). This classifier panel includes His, Trp, 
C18:1, lysoPC a C18:2, PC aa C32:2, PC aa C34:4, and PC ae C34:3. The diagonal dot-
dashed gray line means no separation ability, i.e. random classification. 
 
The performance of this seven metabolites classification model in discriminating OVCA 
patients from PBC patients was also evaluated. The ROC curve analysis for OVCA and PBC 
patients separation achieved an AUC of 0.93 (95% CI: 0.88 ~ 0.98) (Figure 4.16, left). At the 
same time, OVCA patients at the early and late stages were also investigated. Early-stage 
OVCA and PBC patients distinction had a relatively low AUC of 0.70 (95% CI: 0.57 ~ 0.83) 
(Figure 4.16, middle). However, the discriminatory power between late-stage OVCA and 
PBC patients could be as high as AUC = 0.943 (95% CI: 0.88 ~ 1.00) (Figure 4.16, right).  
The low number of early-stage OVCA samples might be the reason for their low performance, 
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and the reason for the similar discriminative ability between late-stage and overall OVCA 
patients.    
 
 
Figure 4.16: ROC curve for a seven metabolites panel to distinguish between OVCA and 
PBC patients (left), early-stage OVCA and PBC patients (middle), late-stage OVCA and PBC 
patients (right). This classifier panel includes His, Trp, C18:1, lysoPC a C18:2, PC aa C32:2, 
PC aa C34:4, and PC ae C34:3. The diagonal dot-dashed gray line means no separation 
ability, i.e. random classification. 
 
To evaluate the power of each metabolite in discriminating OVCA patients from healthy 
controls or PBC patients, leave-one-out cross-validated ROC analysis for the logistic 
regression model was built in the discovery and validation cohorts (Table 4.5). AUCs of 
early-stage OVCA patients differed a lot from the overall OVCA patients because of the 
small sample size. Therefore, results for early-stage OVCA patients could not reflect the 
authentic ability of the metabolite panel in differentiating them from healthy controls or PBC 
patients. Each metabolite in the panel performed with high AUC in separating OVCA 
patients from healthy controls or PBC patients (Figure 4.17). However, the multivariate 
model containing these seven metabolites had the highest differentiation power (Figure 4.15; 
Figure 4.16).   
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Figure 4.17: Leave-one-out cross-validated ROC analysis for individual metabolites to 
differentiate OVCA patients from healthy controls or PBC patients. The continuous red line 
and dotted blue line represent the ROC curves for OVCA patients versus healthy controls, 
OVCA patients versus and PBC patients, respectively. The diagonal gray line means no 
separation ability, i.e. random classification. 
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4.4.3 Plasma metabolites associated with OVCA diagnosis identified by 
Biocrates AbsoluteIDQ
®
 p400 HR Kit 
During the process of data analysis, Biocrates released the AbsoluteIDQ® p400 HR Kit. This 
new kit could measure 408 metabolites simultaneously, including 21 amino acids, 21 
biogenic amines, one hexose, 172 phosphatidylcholines, 24 lysophosphatidylcholines, 31 
sphingomyelins, nine ceramides, 55 acylcarnitines, 14 cholesteryl esters, 18 diglycerides, and 
42 triglycerides (Table A5). With the same patient samples, plasma metabolites were again 
measured by the p400 HR kit. The profiling procedure was the same as for the p180 kit, 
which was described in the Methods.   
A total of 248 metabolites were left for downstream analysis after filtering with the same 
criteria. Metabolites concentration data were log2 transformed, and univariate logistic 
regression analysis identified the significantly different metabolites between groups. In the 
end, 133 differentially expressed metabolites between ovarian cancer patients and healthy 
controls were identified in the discovery cohort, and 77 metabolites were verified in the 
validation cohort. These 77 metabolites consisted of eight amino acids, four biogenic amines, 
35 phosphatidylcholines, nine lysophosphatidylcholines, 12 sphingomyelins, two ceramides, 
four acylcarnitines, one cholesteryl ester, one diglyceride, and one triglyceride. Moreover, all 
the metabolites in the classifier panel that measured with the p180 kit to distinguish between 
OVCA patients and healthy controls were also differentially expressed when measured with 
the p400 kit. 
Further, a panel of 17 metabolites was selected by multivariate penalized LASSO 
logistic regression analysis, as with the p180 kit. This discriminative panel contained Ala, 
Asn, Cit, Glu, Trp, ADMA, c4-OH-Pro, SDMA, AC(4:0), AC(16:1), LPC(18:2), PC(34:5), 
PC(35:1), PC(42:4), PC-O(30:0), SM(32:2), and SM(42:1) achieved a high AUC of 0.99 (95% 
CI: 0.97 ~ 1.00) (Figure 4.18). The sensitivity and specificity were higher than the panel 
selected with the p180 kit. Trp and LPC(18:2) were the overlapped metabolites in the classier 
panels that selected with the p180 kit and p400 kit. Likewise, the combination of the classier 
panel performed better than individual metabolites in separating OVCA patients from healthy 
controls (Figure 4.18; Figure 4.19).      
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Figure 4.18: ROC curve for multiparametric panel based on penalized LASSO logistic 
regression model to distinguish ovarian cancer patients from healthy controls. The diagonal 
dot-dashed gray line means no separation ability, i.e. random classification. 
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Figure 4.19: ROC curves of individual metabolites from the classifier panel that measured 
with p400 kit to separate OVCA patients from healthy controls. ROC curves for the 
discovery and validation cohorts are shown with red and blue lines, respectively. The 
diagonal gray line means no separation ability, i.e. random classification. 
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5. Discussion 
Cancer management and treatment have benefited a lot from biomarkers, which have 
improved disease outcomes and the overall life quality of cancer patients. Cancer biomarkers 
have increased the survival rates, for instance, amongst breast cancer patients (Cardoso et al., 
2009; Kataja et al., 2009) and ovarian cancer patients (Ledermann et al., 2018). In addition, 
the prediction of the metastasis risk of cancer patients might facilitate to generate tailored 
treatment (Weigelt et al., 2005). The better prognostic prediction will promote a more 
personalized medicine approach, which is the future of cancer treatment. However, well-
established circulating biomarkers have limited applications. For example, CA15-3, CA27-29, 
and CEA are only appropriate for metastatic breast cancer relapse monitoring and prognosis, 
rather than diagnosis (Bast et al., 2001; Ludwig and Weinstein, 2005). Similarly, FDA 
approved CEA, CA125 and HE4 are markers for ovarian cancer diagnosis and monitoring, 
but lacking high specificity and sensitivity, especially for patients at an early stage (Hogdall, 
2008; Moore et al., 2012; Muinao et al., 2018; Ueland, 2017). Though CTCs are very 
promising prognostic markers of metastatic breast cancer, their detection methods increase 
the false positive and false negative rate (Allan and Keeney, 2010; Cristofanilli et al., 2004). 
Therefore, it is urgent to develop better and more accurate markers for breast cancer and 
ovarian cancer early detection, as well as for metastatic breast cancer early detection and 
prognosis.       
Circulating biomarkers, especially biomarkers in blood, are suitable and practical for 
routine clinical use. Compared to tumor tissues, blood samples can be easily accessed with 
minimally invasive procedures, which is highly appropriate for repeated sampling and 
continuously monitoring. Blood metabolic profile alterations, which have been proposed as 
diagnostic, prognostic, and predictive markers for several cancers including breast cancer and 
ovarian cancer, were investigated (Gunther, 2015; Hart et al., 2017; Loke and Lee, 2018; 
Plewa et al., 2019). Metabolites represent the ultimate changes of the organism and could 
directly reflect the phenotypic properties, which help to elucidate the nature and identity of 
biological processes (Beger, 2013; Capati et al., 2017). This is the most significant advantage 
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of metabolites over other signatures such as somatic DNA mutations, DNA methylations, 
microRNAs, or proteins. Measurement of metabolites by mass spectrometry is fast, sensitive, 
robust, and needs only a very small sample volume. These properties indicate the potential of 
metabolites as biomarkers for breast cancer and ovarian cancer.     
 
 Metabolites Associated with PBC 5.1
Comparative profiling of plasma metabolite levels generated a list of 18 metabolites that were 
significantly different (FDR < 0.05) between PBC patients and healthy controls. In detail, 
increased levels of C2 and C14:1, and decreased levels of Ala, Asn, Glu, His, Leu, Lys, Met, 
Orn, Phe, Thr, Trp, Tyr, Val, Kynurenine, Met-SO and C3 in PBC samples were observed. 
A multi-marker panel is superior to a single marker, because the multi-marker panel is 
more informative, accurate, and stable. The panel of metabolites differentiating PBC patients 
from healthy controls showed that a combination of the discriminatory power of individual 
metabolites resulted in higher performance than each metabolite. An AUC of 0.80 was 
achieved, wherein the models consisted of Glu, Orn, Thr, Trp, Met-SO, C2, and C3 that may 
serve as potential early diagnostic biomarkers of breast cancer. The inclusion of metabolites 
in the final model was based on a penalized automatic variable selection with ten-fold cross-
validation regression analysis. The cross-validation method randomly divides the data into 
training and validation tests, so multiple rounds of cross-validation are performed, reducing 
data variability and over-fitting. This is statistically equivalent to independent validation, so it 
is crucial here because these results are not independently validated. Pathway enrichment 
analysis revealed significant enrichment of 12 pathways, including disturbances in amino 
acid metabolism, aminoacyl-tRNA biosynthesis, and nitrogen metabolism.  
As one of the most prominent discriminatory features, the majority of amino acids in 
plasma of PBC patients were lower than in healthy controls, which is consistent with the 
results of most previous reports of breast cancer patients with lower amino acid amounts than 
healthy controls (Jove et al., 2017; Shen et al., 2013; Wang et al., 2016a; Zhou et al., 2017). 
Lower levels of amino acids might associate with higher protein requests in the cancer cell to 
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support its rapid growth and proliferation (Lai et al., 2005). Another feature of this study is 
the significant increase in fatty acid and lipid levels in PBC patients, relative to those in 
healthy controls, which have been mentioned in other reports (Lv and Yang, 2012; Wang et 
al., 2016a; Zhou et al., 2017).  
 
 Metabolites Associated with MBC 5.2
MBC subgroups defined by CTC status had distinct plasma metabolite profiles, as evident 
from the clustering of samples. Abundances of 19 metabolites for CTC-positive MBC 
samples and 12 metabolites for CTC-negative MBC samples were validated to significantly 
(FDR < 0.05) different from healthy controls. Increased levels of Glu, C4:0, C16:0, C18:1, 
PC aa C40:6 in CTC-positive MBC samples, and Glu, C2:0, C16:0, C18:0, C18:1, C18:2, PC 
aa C40:6 in CTC-negative MBC were observed when compared to healthy controls. On the 
other hand, Asn, His, Trp, and lysoPC a C18:2 were decreased in all MBC samples in 
comparison to healthy controls.  
Multivariate ten-fold cross-validated LASSO regression analysis generated two panels 
of metabolites to distinguish between MBC subgroups and healthy controls. All metabolites 
were allowed to enter the model as penalized variables and retained as long as they have 
unique contributions to the discriminative power of the model. For discriminating CTC-
positive MBC from healthy samples, a combination of His, C4:0, C18:1, lysoPC a C18:2, PC 
aa C40:6, and PC ae C42:3 was postulated with AUC = 0.92. Although the difference 
between CTC-negative MBC and healthy controls were not as high as the CTC-positive 
MBC, combining Asn, Glu, His, Thr, Trp, C16:0, C18:0, C18:1, C18:2, lysoPC a C18:2, and 
PC aa C40:6 could differentiate CTC-negative MBC and control with an AUC of 0.89.  
Metabolites that were different between MBC subgroups and PBC patients exhibited 
many overlaps with those between MBC subgroups and healthy controls. Among the 25 
significantly different metabolites, a combination of Arg, Glu, Orn, C4:0, lysoPC a C18:2, 
lysoPC a C20:4, PC aa C40:6, PC aa C42:1, PC ae C34:2, PC ae C34:3, PC ae C36:3, PC ae 
C42:1, PC ae C42:3, PC ae C42:5, and PC ae C44:4 was postulated with AUC = 0.95 for 
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CTC-positive MBC samples, whereas within the nine significantly different metabolites, a 
panel of  Arg, Glu, Orn, Met-SO, spermidine, C4:0, and lysoPC a C18:2 with AUC = 0.90 
was selected for CTC-negative MBC samples compared to PBC samples. Nowadays, MBC 
patient detection depends on the clinical manifestations of disease transmission to distant 
organs, a biopsy of affected organs, imaging methods, radiological assessment, and serum 
tumor markers (Scully et al., 2012). However, these methods are less effective in detecting 
metastasis, especially at the early stage, when the patient could have a better outcome (Scully 
et al., 2012). Serum markers such as CA 15-3 and CEA are widely used to detect the 
development of breast cancer metastasis, however, only useful in 54%-80% and 30%-50% of 
MBC patients, respectively (Lee et al., 2013). In comparison to these markers, the 
performance of our panel of metabolites was much higher for distinguishing subjects with 
MBC from healthy controls or PBC. Thus, the panels of metabolites identified here, if 
verified in large multi-centric prospective studies, might be potential diagnostic markers, 
which would have important applications in identifying early-stage MBC patients or micro-
metastatic patients without clinically overt metastasis, which are usually missed by imaging 
techniques. In turn, early capture of the disease might increase the survival rate of patients 
with MBC. 
Phosphatidylcholines were the mostly identified metabolites associated with MBC, and 
they were widely studied in many cancer types (Bertini et al., 2012; Mir et al., 2015). 
However, for breast cancer, they were mostly studied in breast cancer tissues (Brockmoller et 
al., 2012; Hilvo et al., 2011) or blood samples from mice with MBC (Kus et al., 2018), and 
they were present at lower levels in all these studies. lysoPC a C18:2, a 
lysophosphatidylcholine, decreases with the progression of breast cancer. Previous studies 
have claimed that most of the amino acid levels in patients with metastatic breast cancer are 
high (De Luca et al., 2010; Hart et al., 2017; Seidlitz et al., 2009). Dysregulation of 
acylcarnitines has been widely reported in other cancers types, but rarely in MBC blood 
samples (Lu et al., 2016; Shen et al., 2013; Xie et al., 2017). The involvement of here-
identified metabolites in other epithelial cancers raises the questions about their specificity 
for breast cancer and we hypothesize that they might be generally elevated in epithelial 
cancer. 
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 Putative Prognostic Metabolites for MBC 5.3
The prognostic significance of plasma metabolites in MBC patients was investigated and 
characterized by analyzing their correlations with PFS and OS. Disease progression 
quantified as PFS is one of the original four categorical outcomes developed by the WHO to 
describe changes in tumor burden (Miller et al., 1981). Determination of whether the disease 
has progressed or not was established based on the RECIST guideline in the MBC cohort 
(Eisenhauer et al., 2009). PFS and OS are important outcomes in advanced cancers wherein 
PFS and OS are related to quality and quantity of life for cancer patients, respectively (Booth 
and Eisenhauer, 2012; Siena et al., 2007).   
Within MBC patients, metabolites that were differentially expressed between patients 
with poor and good prognosis correlated with PFS, while metabolites that were differentially 
expressed between deceased and alive patients correlated with OS. Log-rank tests were 
applied to metabolites data stratified into lower quartile and the residual quartiles based on 
their concentrations. A list of four metabolites, kynurenine, PC aa C36:3, PC ae C36:1, and 
PC ae C38:3, correlated with PFS and 12 metabolites, lysoPC a C18:1, lysoPC a C20:3, 
lysoPC a C20:4, PC aa C36:3, PC aa C36:4, PC aa C38:5, PC ae C36:1, PC ae C38:3, PC ae 
C38:4, PC ae C40:2, SM C18:1, and SM (OH) C22:2, correlated with OS. Kaplan-Meier 
curves indicated that lower levels of the metabolites correlated with the lower probability of 
PFS and OS, namely, a shorter progress-free survival time and a shorter overall survival time.   
Penalized LASSO Cox regression analysis was carried out to predict putative metabolite 
combinations from these prognostic metabolites with optimal performance. Signatures of PC 
ae C36:1 and PC ae C38:3 for PFS, lysoPC a C20:3, lysoPC a C20:4, PC aa C38:5, PC ae 
C38:3, and SM (OH) C22:2 for OS were put forth by these analyses. To understand the 
performance of metabolite panels associated with currently available markers, they were 
compared to CTC status, which is an established and FDA approved prognostic marker for 
MBC (Allard et al., 2004). Evaluating the IPE of the model with metabolites or CTC status 
proved that the metabolite signatures (IPE = 5.669) performed not as well as CTC status (IPE 
= 5.628) for PFS, the difference in IPE between the metabolite panel (IPE = 5.795) and the 
CTC status (IPE = 5.268) was much wider for OS. Next, a panel combining both metabolite 
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variables and CTC status was built. Here, as we found no significant interaction between 
metabolites and CTC status, interaction between the metabolites and CTC status was ignored. 
The results showed that the combination of the CTC status and the metabolite panel largely 
diminish the prediction error in comparison to the CTC-status alone or metabolite profile 
alone. It is interesting to note that the best-fitting multivariable models for PFS were PC ae 
C36:1 and CTCs (5.535), for OS were lysoPC a C20:3 and CTCs (5.082). This study is the 
first to explore the associations of metabolite and CTC status combination with breast cancer 
prognosis.  
Prognostic significance of plasma phospholipids and sphingolipids has been 
demonstrated in breast cancer and other cancers (Bertini et al., 2012; Bilal et al., 2019; Hilvo 
et al., 2011; Ruckhaberle et al., 2008; Zaimenko et al., 2019). Serum phosphatidylcholine 
levels decreased in breast cancer patients after systemic chemotherapy (Li et al., 2017b). The 
lower stearic acid level in tumor membrane phosphatidylcholine, which related to the fatty 
acid composition of phosphatidylcholine, indicates poor breast cancer prognosis (Bougnoux 
et al., 1992). Besides, a study revealed that the survival of patients with metastatic lung and 
gastrointestinal cancers correlates with low levels of total plasma phospholipids (Murphy et 
al., 2010), which supports our hypothesis. This result is consistent with previous studies 
showing that higher plasma levels of lysophosphatidylcholines are related to a lower risk of 
several cancer types, including breast cancer (Kuhn et al., 2016; Zhao et al., 2007). In 
addition, higher levels of sphingomyelins were reported to be significantly associated with 
better DFS in triple-negative breast cancer patients (Purwaha et al., 2018), which is in 
concordance with our results. In future, large multi-centric cohorts will be needed to test the 
reproducibility of our results.  
 
 Metabolites Associated with OVCA 5.4
Next, we identified metabolites associated with ovarian cancer. A panel of seven metabolites, 
including His, Trp, C18:1, lysoPC a C18:2, PC aa C32:2, PC aa C34:4, PC ae C34:3, could 
distinguish ovarian cancer patients from healthy controls with an AUC of 0.95. Such a high 
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performance raises the hope that the identified metabolites, if they can be validated in large 
prospective studies, can prospectively indicate the existence of ovarian cancer at an earlier 
stage than ovarian cancers are diagnosed today. Moreover, this panel of metabolites could 
distinguish OVCA patients from PBC patients as well, which indicates their OVCA-specific 
discriminative feature. In addition, the measurement of plasma metabolites with p400 kit has 
extended the library of potential candidate markers. Currently, no sufficient screening 
strategy has been established for OVCA. CA125 and HE4 are the two blood-based protein 
markers for OVCA monitoring approved by FDA (Ueland, 2017). However, screening with 
CA125 or vaginal ultrasound did not show a significant mortality reduction (Jacobs et al., 
2016), and nowadays, CA125 is only used as an indicator of disease recurrence due to its 
limitation in specificity and sensitivity (Suh et al., 2010). Serum HE4 levels are changing 
with aging, different menopausal status, and pregnancy, which lower the specificity of HE4 
(Moore et al., 2012). The multivariate index assay demonstrated lower specificity compared 
with physician assessment and CA 125 in detecting ovarian malignancies (Ueland et al., 
2011). 
Levels of lipid alterations are usually associated with cancer progression (Chen et al., 
2016; Zhang et al., 2016). Lipid metabolism is increasingly required for cell membranes and 
cell signaling construction during rapid cell proliferation and apoptosis (Zhang et al., 2018). 
In our study, the decreased levels of lipids in OVCA patients, especially phospholipids, are 
associated with an increased risk for ovarian cancer. Similar results have been partially 
presented before (Bachmayr-Heyda et al., 2017; Fan et al., 2016a; Gaul et al., 2015; Plewa et 
al., 2019). Lysophosphatidylcholine is an important signaling molecule for cellular 
proliferation, inflammation, and cell invasion regulation (Li et al., 2017a). 
Phosphatidylcholine, another critical signaling molecule, regulates cell signaling and 
structural integrity of cell membranes (Li et al., 2017a). Previous studies provided evidence 
of the associations between amino acid levels and OVCA metabolism, which demonstrated 
that blood amino acid profiles might be useful for ovarian cancer detection (Plewa et al., 
2017; Zhou et al., 2010). Our present study also observed correlations between decreased Ala, 
Asn, Cit, His, Trp, and Tyr levels and increased ovarian cancer risk, except for Glu. 
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 Functional Relevance of Identified Metabolites 5.5
Amino acids, being both metabolic fuel and building blocks of protein synthesis, have been 
proposed as predominant participants in the development of cancer (Lai et al., 2005). In 
general, amino acids decreased in PBC patients but increased in MBC and OVCA patients in 
our study. Hart et al. investigated higher levels of most amino acids in metastatic breast 
cancer patients than the ones at the early stage, which supports our results (Hart et al., 2017). 
Bone metastasis of breast cancer exhibits increased secretion of glutamate into the 
extracellular environment, which contributes to the disruption of normal bone homeostasis 
(Seidlitz et al., 2009).  
The increased activity of arginase and ornithine decarboxylase might explain the lower 
amount of arginine and the higher level of spermidine (Miolo et al., 2016; Perez et al., 2012). 
Methionine is a major target of reactive oxygen species (ROS), leading to the formation of 
Met-SO (Moskovitz, 2005). During breast cancer metastasis, a decreased amount of 
methionine sulfoxide reductases causes Met-SO to accumulate (De Luca et al., 2010). 
Tryptophan may originate from an increased metabolization via the indoleamine-2,3-
dioxygenase to kynurenine or via tryptophan-hydroxylase to serotonin (O'Mahony et al., 
2015). Tryptophan is particularly unexpected in early-stage cancer patients, as it is associated 
with cancer progression (Miyagi et al., 2011). Kynurenine not only promotes epithelial-to-
mesenchymal transition via activating aryl hydrocarbon receptor but also promotes the 
degradation of E-cadherin by enhancing the formation of the E-cadherin/AhR/Skp2 complex. 
These processes are believed to play vital roles in cancer invasiveness and metastasis (Chen 
et al., 2014; Duan et al., 2018).  
Glutamate, the interchangeable substrate of glutamine, was significantly lower in PBC 
patients, whereas significantly higher in metastatic breast cancer and ovarian cancer patients 
was observed by us. Glutaminolysis is one of the distinctive central features of cancer 
metabolism (Cluntun et al., 2017). Thereby glutamine is converted via glutamate to α-
ketoglutarate, which enters the tricarboxylic cycle to produce energy and anabolic carbons for 
the synthesis of amino acids, nucleotides, and lipids (Jin et al., 2016). These biological 
processes may partially explain the change of glutamate levels in our results.  
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The putrescine is a polyamine product from ornithine that catalyzed by ornithine 
decarboxylase, which exists in breast cancer cells and other cancer types (Afshar et al., 2017; 
Kim et al., 2017). Polyamine is indispensable for normal cell growth and development, and 
its elevated level has been observed to associate with several cancer types(Luk and Casero, 
1987). We observed a lower level of ornithine in PBC patients, which possibly due to its 
conversion to polyamine.  
Compared to healthy controls, PBC patients have significantly lower threonine 
concentrations in our study. We speculate that this may be a sign of increased production of 
pyruvate from threonine, which also associated with impaired glutamate uptake in a previous 
study (Poschke et al., 2013). On the other hand, threonine also has a role in immunoglobulin 
production (Wils-Plotz et al., 2013). The gut may absorb a large proportion of dietary 
threonine for the production of immunoglobulins because of disease or treatment. This is an 
interesting perspective and future research is needed to assess this possibility.  
Acylcarnitines play an essential role in regulating the balance between intracellular 
carbohydrate and lipid metabolism (Li et al., 2019). Increased concentrations of 
acylcarnitines hint an excess of acetyl-CoA in cancer cells, which are converted to C2 by the 
carnitine O-acetyltransferase with subsequent excretion (Pietrocola et al., 2015). As acetyl-
CoA inhibits pyruvate dehydrogenase and induces gluconeogenesis, so its accumulation is 
undesirable in cancer cells (Li et al., 2014; Schug et al., 2015). In order to cross the 
mitochondrial matrix for fatty acid β-oxidation, which produces energy to maintain cancer 
progression, long-chain fatty acids must be conjugated to carnitine to form long-chain 
acylcarnitines (Schug et al., 2015). We speculate that this process leads to the accumulation 
of long-chain acylcarnitines observed in cancer plasma. Compared to healthy controls, less 
free carnitine and odd number short-chain acylcarnitines C3 and C5 were observed by us in 
the plasma of PBC patients because the conjugation of medium- and long-chain acyl groups 
to free carnitine (C0). Similar results had demonstrated that several acylcarnitines associated 
with β-oxidation showed higher plasma concentrations in breast cancer patients than in 
healthy controls (Lv and Yang, 2012; Shen et al., 2013). 
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In our study, the majority of the identified metabolites associated with MBC and OVCA 
were phosphatidylcholines. OVCA and CTC-positive patients showed lower levels of 
phosphatidylcholines, so we speculate that phosphatidylcholines participate in the metastasis 
of cancer, especially in the late stage. Indeed, a study showing that the survival of patients 
with metastatic lung and gastrointestinal cancers correlates with low levels of total plasma 
phospholipids supports our hypothesis (Murphy et al., 2010). Currently, few 
phosphatidylcholines have been investigated in human breast cancer blood samples. Most of 
them were studied either in breast cancer tissues (Brockmoller et al., 2012; Hilvo et al., 2011) 
or blood samples derived from mice with MBC (Kus et al., 2018). Phosphatidylcholines were 
present at lower levels in all these studies. Lower levels of phosphatidylcholines were also 
observed in OVCA patients (Fan et al., 2016a). Phosphatidylcholines are one of the most 
abundant glycerophospholipids in human cells, which are essential components of the cell 
membrane, maintaining its integrity and functions. Phosphatidylcholines play a crucial role in 
cell proliferation and apoptosis (Ridgway, 2013). Also, we found lysoPC a C18:2, one of the 
lysophosphatidylcholines, decreases as breast cancer progressed. This result is consistent with 
previous studies showing that higher plasma levels of lysophosphatidylcholines are related to 
a lower risk of several cancer types, including breast cancer (Kuhn et al., 2016; Zhao et al., 
2007). 
 
 Strengths and Limitations of the Study 5.6
The significant strength of this project is that the samples were carefully collected and 
processed. Pre-analytical conditions play a vital role in investigating blood metabolites and 
are one of the main reasons for the lack of reproducibility in results among studies (Santos 
Ferreira et al., 2019). According to a previous report and our experience, the processing of 
blood samples within two hours after blood collection and two-step centrifugation before 
snap-freezing are critical to avoid hemolysis and metabolite contamination from cells or cell 
debris (Yin et al., 2013). This protocol is designed to make sure that the metabolites 
originated from the cell-free portion of the blood exclusively. Sample preparation is of 
translational importance as not all samples are prepared ideally in a clinical setting, so the 
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newly speculated markers need to be able to buffer such differences. The choice of plasma as 
the sample type is also one of the advantages. Serum is more sensitive than plasma in 
metabolomics study because most metabolites have higher concentrations in serum (Liu et al., 
2010; Yu et al., 2011). However, partly this higher metabolite levels are suspected to 
originate from metabolites that have been released from cells or cell debris into the serum 
during sampling, as plasma is more reproducible than serum, which is quite popular in the 
biomarker study (Yu et al., 2011).   
The other significant advantage of this study is the systematic study design consisting of 
the discovery and validation phase. Plasma metabolites were profiled in both phases with 
identical experimental procedures independently to demonstrate metabolites that have 
potential diagnostic and prognostic values. Sample randomization through all steps of the 
experimental setup was done to avoid batch variations and, thus, any possible bias. The large 
sample size of breast cancer patients is another positive aspect. Additionally, the prognostic 
metabolites were validated in an independent sample group for their association with PFS and 
OS, which consolidate the validity of our results. 
One major drawback of the study is that, with this experiment, the length of side chains, 
distribution and position of double bonds of metabolites cannot be discerned. Thus, the exact 
conformations of metabolites are unknown. In addition, this kit identifies many metabolites 
with functions not well known currently. As a result, the reason why they appear in the blood 
or plasma is hard to explain.   
Another limitation of the study is the lack of lifestyle and physiological information of 
cancer patients. Thus we cannot adjust all the confounding factors with the univariate and 
multivariate logistic regression analysis. In the study, we have identified panels of 
metabolites as supposed diagnostic and prognostic markers with high performance. However, 
whether they are specific for their corresponding cancer type is unknown. Furthermore, no 
animal model experiment was conducted to explain or investigate our results concerning the 
underlying mechanism.  
Last but not least, the sample size of OVCA patients, especially early-stage OVCA 
samples, is relatively low. Therefore, the metabolite panel identified here fits the late-stage 
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OVCA patients better. This limitation reflects the general diagnosis of ovarian cancer at a 
relatively late stage. In our study, we focused on OVCA patients with rather an early-stage 
diagnosis. But as the sample size would have been too small, we had to include also even 
more advanced-stage samples. Large studies including more early-stage OVCA patients as 
well as large prospective studies are needed to identify and verify metabolites for early-stage 
detection. The fact that no significant metabolites were detected between breast tumor 
molecular subgroups may be due to the uneven distribution of samples between subgroups, 
resulting in relatively small sample sizes of rare subgroups. Large cohorts in the future 
including enough samples of even rare breast cancer subgroups are needed.    
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6. Perspectives  
Identified metabolite panels associated with PBC, MBC, and OVCA patients and MBC 
prognosis are needed to be further validated with independent and more extensive multi-
centric prospective studies. Metabolites connected with breast cancer and ovarian cancer 
from different layers could extend to other epithelial cancers. Therefore, population-based 
metabolomics studies are essential to be conducted. Especially prognostic metabolites for 
metastatic breast cancer should be analyzed in epithelial cancers that also use CTC status as 
prognostic factors for metastasis, such as prostate cancer and colorectal cancer.  
In this project, metabolites of different combinations are speculated as promising 
biomarkers for breast cancer and ovarian cancer. However, whether these combinatorial 
panels are specific for the corresponding cancer types needs to be further verified. Plasma 
metabolite profiles are also affected by patient lifestyles, physiological status, and 
environmental factors. Unfortunately, this information was not available for most of the 
cancer patients in our study. Investigations in the future should be applied to adjust all 
meaningful confounding factors. Moreover, higher mass resolution methods need to be 
employed to measure the exact composition of lipids. Metabolites that measured with 
Biocrates AbsoluteIDQ® p400 HR kit for breast cancer patients will be analyzed in the future 
to expand the library of breast cancer diagnostic and prognostic biomarkers.  
It might be promising and illuminating to combine metabolomics data and 
transcriptomics data, together with genomics data, to explore the underlying mechanisms of 
metabolic changes. The multi-omics analysis will not only deepen our understanding of the 
metabolic processes of breast cancer and ovarian cancer but also likely help to develop new 
therapeutic targets for cancer treatment. The functional characterization of the metabolites 
identified in this project may promote understanding of the biological processes in cancer 
occurrence and development. Further, the combination of metabolites with other promising 
blood-based molecular markers, such as DNA methylation, microRNA, cell-free DNA 
mutation markers, will be an attractive option. Multimarkers from different layers could be 
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potentially useful in developing blood-based diagnostic tests for breast cancer and ovarian 
cancer. 
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Appendix  
Detailed Clinical Features of Samples 
Table A1: Clinicopathological characteristics of the PBC patients in discovery and validation 
cohorts. aChi-squared test, bWilcoxon rank-sum test, ctests with p < 0.05. 
Clinical Characteristics Discovery 
Cohort 
(n = 80) 
Validation 
Cohort 
(n = 109) 
p-value 
 
Ageb 
Mean 
Median 
Range  
55.6 
53.0 
30.6 ~ 84.4 
50 
46.2 
26.8 ~ 77.4 
 
0.001c 
 
Menopausea 
Premenopause 
Perimenopause 
Postmenopause 
NA 
29 (36.3%) 
8 (10.0%) 
42 (52.5%) 
1 (1.3%) 
61 (56.0%) 
7 (6.4%) 
39 (35.8%) 
2 (1.8%) 
 
 
0.055 
 
 
Gradinga 
G1 
G2 
G3 
NA 
6 (7.5%) 
38 (47.5%) 
36 (45.0%) 
0 
12 (11.0%) 
53 (48.6%) 
43 (39.4%) 
1 (0.9%) 
 
 
0.641 
 
 
 
Tumor sizea 
Tis 
T1 
T2 
T3 
T4 
2 (2.5%) 
29 (36.3%) 
44 (55.0%) 
5 (6.3%) 
0 
1 (0.9%) 
45 (41.3%) 
55 (50.5%) 
3 (2.8%) 
5 (4.6%) 
 
 
0.184 
Lymph node 
spreada 
N0 
N1 
N2 
57 (71.3%) 
22 (27.5%) 
1 (1.3%) 
72 (66.1%) 
35 (32.1%) 
2 (1.8%) 
 
0.738 
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AJCC stagea 
0 
I 
II 
III 
IV 
NA 
2 (2.5%) 
23 (30.0%) 
48 (60.0%) 
3 (3.8%) 
3 (3.8%) 
1 (1.25%) 
1 (0.9%) 
37 (33.9%) 
62 (56.9%) 
9 (8.3%) 
0 
0 
 
 
 
0.159 
 
 
ER statusa 
Positive 
Negative 
NA 
46 (57.5%) 
33 (41.3%) 
1 (1.3%) 
80 (73.4%) 
29 (26.6%) 
0 
 
0.047c 
 
 
PR statusa 
Positive 
Negative 
NA 
43 (53.8%) 
36 (45.0%) 
1 (1.3%) 
74 (67.9%) 
35 (32.1%) 
0 
 
0.087 
 
 
HER2 statusa 
Positive 
Negative 
NA 
16 (20.0%) 
63 (78.8%) 
1 (1.3%) 
30 (27.5%) 
79 (72.5%) 
0 
 
0.262 
 
 
Triple negativea 
Yes 
No 
NA 
20 (25%) 
59 (73.8%) 
1 (1.3%) 
25 (22.9%) 
84 (77.1%) 
0 
 
0.470 
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Table A2: Clinicopathological characteristics of the MBC patients in discovery and 
validation cohorts. aChi-squared test, bWilcoxon rank-sum test, ctests with p < 0.05. 
 
Clinical characteristics  
Discovery Cohort (n=100) Validation Cohort (n=76) 
CTC-
positive  
(n=44) 
CTC-
negative 
(n=56) 
p-
value 
CTC-
positive 
(n=21) 
CTC-
negative 
(n=55) 
p-
value 
 
Ageb 
Mean 57.25 60.63  
0.17 
59.86 58.96  
0.74 Median 56 62 57 59 
Range 33 ~ 81 31 ~ 89 42 ~ 77 36 ~ 78 
Bone 
metastasis a 
Yes 34 33  
0.09 
16 32  
0.23 No 10 23 5 23 
Lung 
metastasis a 
Yes 13 29  
0.04c 
12 31  
1 No 31 27 9 24 
Liver 
metastasis a 
Yes 22 20  
0.22 
10 18  
0.35 No 22 36 11 37 
Brain 
metastasis a 
Yes 4 7  
0.83 
0 5  
0.36 No 40 49 21 50 
Number of 
sites of 
metastasis a 
1-2 25 33  
0.97 
10 32  
0.57 3-5 18 22 11 23 
> 5 1 1 0 0 
 
Disseminated 
metastasis a 
Yes 34 22  
0.0003
c 
16 43  
0.78 No 10 34 5 11 
NA 0 0 0 1 
 
Metastatic 
ER status a 
Positive 17 26  
0.64 
10 24  
0.6 Negative 6 5 1 7 
NA 21 25 10 24 
 
Metastatic 
PR status a 
Positive 14 22  
0.71 
8 17  
0.57 Negative 9 9 3 14 
NA 21 25 10 24 
 
Metastatic 
HER2 status a 
Positive 3 8  
0.49 
1 8  
0.5 Negative 21 25 10 23 
NA 20 23 10 24 
 
PFS status a 
Progression 27 34  
1 
18 48  
1 No 
Progression 
17 22 3 7 
PFS (Month) b Mean 14.2 6.4  5.45E-
04 c 
8.2 4.5  0.24 
 
OS status a 
Dead 35 25  
8.66E-
04 c 
19 24  
6.14E-
04 c 
Alive 9 31 2 31 
OS (Month) b Median 23.3 11.3 2.69E-
07 c 
21.5  11.4 1.3E-
04 c 
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Prognosis 
status a 
Good 8 23  
0.048 c 
2 13  
0.39 Bad 26 17 17 34 
Middle 10 16 2 8 
 
 
Histology a 
 
IDC 19 31  
 
0.02c 
13 31  
 
0.73 
ILC 8 4 1 7 
Others  5 0 1 4 
NA 12 21 6 13 
 
 
Grading a 
G1 1 4  
 
0.14 
0 2  
 
0.56 
G2 26 21 9 25 
G3 14 23 7 21 
NA 3 8 5 7 
 
 
 
Tumor size a 
 
Tis 1 0  
 
 
0.34 
0 0  
 
 
0.36 
T1 12 25 7 10 
T2 21 22 9 29 
T3 6 4 0 5 
T4 4 4 4 7 
NA 0 1 1 4 
 
 
Lymph node 
spread a 
 
N0 20 21  
 
 
0.45 
6 21  
 
 
0.84 
N1 11 22 7 16 
N2 3 5 3 8 
N3 8 5 4 6 
NA 2 3 1 4 
 
Distant 
metastasis a 
M0 19 29  
0.69 
11 29  
1 M1 8 9 6 15 
NA 17 18 4 11 
 
Primary ER 
status a 
Positive 31 45  
0.14 
18 38  
0.25 Negative 13 9 2 15 
NA 0 2 1 2 
 
Primary PR 
status a 
Positive 25 42  
0.02c 
14 33  
0.59 Negative 19 11 5 19 
NA 0 3 2 3 
Primary 
HER2 
status a 
Positive 4 9  
0.33 
0 11  
0.05 Negative 37 40 16 38 
NA 3 7 5 6 
DFS (Month) 
b 
Median 28 46 0.06 51 45 0.66 
DDFS 
(Month) b 
Median 29 70.5 0.006c 79 50 0.83 
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Table A3: Clinicopathological characteristics of the ovarian cancer patients in discovery and 
validation cohorts. aChi-squared test, bWilcoxon rank-sum test, ctests with p < 0.05. 
Clinical Characteristics 
Discovery Cohort 
(n=34) 
Validation Cohort 
(n = 35) 
p-value 
Ageb 
Mean 61.2 61.6 
0.889 Median 62.6 64.5 
Range 37.5 ~ 77 25.5 ~ 83.6 
FIGO 
staginga 
I 2 (5.9%) 5 (14.3%) 
0.006c 
II 1 (2.9%) 5 (14.3%) 
III 29 (85.3%) 15 (42.9%) 
IV 2 (5.9%) 6 (17.1%) 
NA 0 4 (11.4%) 
Gradinga 
G1 1 (2.9%) 3 (8.6%) 
0.111 
G2 7 (20.6%) 1 (2.9%) 
G3 21 (61.8%) 24 (68.6%) 
NA 5 (14.7%) 7 (20%) 
Diabetesa 
Yes 5 (14.7%) 1 (2.9%) 
0.214 No 26 (76.5%) 30 (85.7%) 
NA 3 (8.8%) 4 (11.4%) 
BMIb 
Mean 25.7 26 
0.842 
Median 24.8 25 
Range 19.2 ~ 42 19.5 ~ 42.5 
NA 9 (26.5%) 10 (28.6%) 
Menopausea 
Premenopause 
 
3 (8.8%) 6 (17.1%) 
0.382 
Perimenopause 
 
1 (2.9%) 0 
Postmenopause 
 
24 (70.6%) 26 (74.3%) 
NA 6 (17.6%) 3 (8.6%) 
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Metabolites List  
Table A4: List of metabolites measured with Biocrates AbsoluteIDQ® p180 kit. 
Category N  Metabolites 
Amino Acids 21 Ala, Arg, Asn, Asp, Cit, Gln, Glu, Gly, His, Ile, Leu, Lys, 
Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val 
Biogenic Amines 21 alpha-AAA, ADMA, Ac-Orn, carnosine, creatinine, DOPA, 
dopamine, histamine, kynurenine, Met-SO, Nitro-Tyr, cis-OH-
Pro, trans-OH-Pro, PEA, putrescine, SDMA, sarcosine, 
serotonin, spermidine, spermine, taurine 
Carnitine 1 C0 
Acylcarnitines 
(Cx:y) 
26 C2, C3, C3:1, C4, C4:1, C5, C5:1, C6 (or C4:1-DC), C6:1, C8, 
C8:1, C9, C10, C10:1, C10:2, C12, C12:1,C14, C14:1, C14:2, 
C16, C16:1, C16:2, C18, C18:1,C18:2 
Hydroxy- and 
Dicarboxy- 
Acylcarnitines 
(Cx:y-DC/OH) 
13 C3-OH, C4-OH (or C3-DC), C5-DC (or C6-OH), C5-OH (or 
C3-DC-M), C5:1-DC, C5-M-DC, C7-DC, C12-DC, C14:1-
OH, C14:2-OH, C16:1-OH, C16:2-OH, C16-OH, C18:1-OH 
Sum of Hexoses (H1) 1 H1 
Sphingomyelins 
(SM Cx:y) 
10 SM  
C16:0/ C16:1/ C18:0/C18:1/ C20:2/ C22:3/ C24:0/ C24:1/ 
C26:0/C26:1 
Hydroxy- 
Sphingomyelins (SM 
(OH) Cx:y) 
5 SM (OH)  
C14:1/ C16:1/ C22:1/ C22:2/ C24:1 
Diacyl-
Phosphatidylcholines 
(PC aa Cx:y) 
38 PC aa  
C24:0/C26:0/C28:1/C30:0/C30:2/C32:0/C32:1/C32:2/C32:3/C
34:1/C34:2/C34:3/C34:4/C36:0/C36:1/C36:2/C36:3/C36:4/C3
6:5/C36:6/C38:0/C38:1/C38:3/C38:4/C38:5/C38:6/C40:1/C40:
2/C40:3/C40:4/C40:5/C40:6/C42:0/C42:1/C42:2/C42:4/C42:5/
C42:6 
Acyl-alkyl- 
Phosphatidylcholines 
(PC ae Cx:y) 
38 PC ae  
C30:0/C30:1/C30:2/C32:1/C32:2/C34:0/C34:1/C34:2/C34:3/C
36:0/C36:1/C36:2/C36:3/C36:4/C36:5/C38:0/C38:1/C38:2/C3
8:3/C38:4/C38:5/C38:6/C40:1/C40:2/C40:3/C40:4/C40:5/C40:
6/C42:0/C42:1/C42:2/C42:3/C42:4/C42:5/C44:3/C44:4/C44:5/
C44:6 
Lyso-
phosphatidylcholines 
(lysoPC a Cx:y) 
14 lysoPC a  
C14:0/C16:0/C16:1/C17:0/C18:0/C18:1/C18:2/C20:3/C20:4/C
24:0/C26:0/C26:1/C28:0/C28:1 
 
Abbreviations: 
a, acyl; aa, acyl-acyl; ae, acyl-alkyl; 
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DC, decarboxyl groups; M, methyl; OH, hydroxyl groups; 
PC, phosphatidylcholine; SM, sphingomyelin; 
x:y, x is the number of carbons and y is the number of double bonds in the fatty acid side chain 
 
Table A5: List of metabolites measured with Biocrates AbsoluteIDQ® p400 HR kit. 
Category N  Metabolites 
Amino Acids 21 Ala, Arg, Asn, Asp, Cit, Gln, Glu, Gly, His, Ile, xLeu, Lys, 
Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val 
Biogenic Amines 21 alpha-AAA, ADMA, Ac-Orn, carnosine, creatinine, DOPA, 
dopamine, histamine, kynurenine, Met-SO, Nitro-Tyr, cis-
OH-Pro, trans-OH-Pro, PEA, putrescine, SDMA, sarcosine, 
serotonin, spermidine, spermine, taurine 
Sum of Hexoses (H1) 1 H1 
Diacyl-
Phosphatidylcholines 
PC(x:y) 
108 PC  
(24:0)/(25:0)/(26:0)/(27:0)/(27:1)/(28:1)/(29:0)/(29:1)/(29:2)/
(30:0)/(30:1)/(30:2)/(30:3)/(31:0)/(31:1)/(31:2)/(31:3)/(32:0)/
(32:1)/(32:2)/(32:3)/(32:4)/(32:5)/(32:6)/(33:0)/(33:1)/(33:2)/
(33:3)/(33:4)/(33:5)/(34:0)/(34:1)/(34:2)/(34:3)/(34:4)/(34:5)/
(35:0)/(35:1)/(35:2)/(35:3)/(35:4)/(35:5)/(36:0)/(36:1)/(36:2)/
(36:3)/(36:4)/(36:5)/(36:6)/(37:0)/(37:1)/(37:2)/(37:3)/(37:4)/
(37:5)/(37:6)/(37:7)/(38:0)/(38:1)/(38:2)/(38:3)/(38:4)/(38:5)/
(38:6)/(38:7)/(39:0)/(39:1)/(39:2)/(39:3)/(39:4)/(39:5)/(39:6)/
(39:7)/(40:1)/(40:2)/(40:3)/(40:4)/(40:5)/(40:6)/(40:7)/(40:8)/
(40:9)/(41:1)/(41:2)/(41:3)/(41:4)/(41:5)/(41:8)/(42:0)/(42:1)/
(42:2)/(42:3)/(42:4)/(42:5)/(42:6)/(42:7)/(42:10)/(43:2)/(43:6
)/(44:1)/(44:3)/(44:5)/(44:6)/(44:7)/(44:10)/(44:12)/(46:1)/(4
6:2) 
Acyl-alkyl- 
Phosphatidylcholines 
PC-O-(x:y) 
64 PC-O-  
(26:0)/(26:1)/(28:0)/(28:1)/(29:0)/(30:0)/(30:1)/(30:2)/(31:0)/
(31:1)/(31:3)/(32:0)/(32:1)/(32:2)/(32:3)/(33:0)/(33:1)/(33:2)/
(33:3)/(33:4)/33:6)/(34:0)/(34:1)/(34:2)/(34:3)/(34:4)/(35:3)/(
35:4)/(36:0)/(36:1)/(36:2)/(36:3)/(36:4)/(36:5)/(36:6)/(37:6)/(
37:7)/(38:0)/(38:1)/(38:2)/(38:3)/(38:4)/(38:5)/(38:6)/(40:0)/(
40:1)/(40:2)/(40:3)/(40:4)/(40:5)/(40:6)/(40:7)/(40:8)/(42:0)/(
42:1)/(42:2)/(42:3)/(42:4)/(42:5)/(42:6)/(44:3)/(44:4)/(44:5)/(
44:6) 
Lyso-
phosphatidylcholines 
LPC(x:y) 
24 LPC 
(12:0)/(14:0)/(15:0)/(16:0)/(16:1)/(17:0)/(17:1)/(18:0)/(18:1)/
(18:2)/(20:0)/(20:1)/(20:2)/(20:3)/(20:4)/(22:5)/(22:6)/(24:0)/
(24:1)/-O(16:1)/ -O(17:1)/ -O(18:0)/ -O(18:1)/ -O(18:2) 
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Sphingomyelins 
SM(x:y) 
31 SM  
(30:1)/(31:0)/(31:1)/(32:1)/(32:2)/(33:1)/(33:2)/(34:1)/(34:2)/
(35:1)/(36:0)/(36:1)/(36:2)/(37:1)/(38:1)/(38:2)/(38:3)/(39:1)/
(39:2)/(40:1)/(40:2)/(40:4)/(41:1)/(41:2)/(42:1)/(42:2)/(42:3)/
(43:1)/(43:2)/(44:1)/(44:2) 
Ceramides 
Cer(x:y)  
9 Cer 
(34:0)/(34:1)/(38:1)/(40:1)/(41:1)/(42:1)/(42:2)/(43:1)/(44:0)/ 
Acylcarnitines 
AC(x:y) 
34 AC 
(0:0)/(2:0)/(3:0)/(3:1)/(4:0)/(4:1)/(5:0)/(5:1)/(6:0)/(6:1)/(7:0)/
(8:0)/(8:1)/(9:0)/(10:0)/(10:1)/(10:2)/(10:3)/(11:0)/(12:0)/(12:
1)/(13:0)/(14:0)/(14:1)/(14:2)/(15:0)/(16:0)/(16:1)/(16:2)/(17:
0)/(18:0)/(18:1)/(18:2)/(19:0) 
Hydroxy- and 
Dicarboxy- 
Acylcarnitines 
AC(x:y-DC/OH) 
21 AC 
(3:0-DC)/(3:0-OH)/(4:0-DC)/(4:0-OH)/(4:1-DC)/(5:0-DC)/ 
(5:0-OH)/ (5:1-DC)/ (6:0-DC)/(6:0-OH)/(7:0-DC)/(8:1-OH)/ 
(12:0-DC)/(14:0-OH)/(14:1-DC)/(14:1-OH)/(14:2-
OH)/(16:0-OH)/(16:1-OH)/(16:2-OH)/(18:1-OH) 
Diglycerides 
DG(x:y) 
18 DG 
(32:1)/(32:2)/(34:1)/(34:3)/(36:2)/(36:3)/(36:4)/(38:0)/(38:5)/
(39:0)/(41:1)/(42:0)/(42:1)/(42:2)/(42:3)/-O(32:2)/-O(34:1)/ -
O(36:4) 
Triglycerides 
TG(x:y) 
42 TG 
(44:1)/(44:2)/(44:4)/(46:2)/(48:1)/(48:2)/(48:3)/(49:1)/(49:2)/
(50:1)/(50:2)/(50:3)/(50:4)/(51:1)/(51:2)/(51:3)/(51:4)/(51:5)/
(52:2)/(52:3)/(52:4)/(52:5)/(52:6)/(52:7)/(53:3)/(53:4)/(53:5)/
(53:6)/ (54:2)/(54:3)/(54:4)/(54:5)/(54:6)/(54:7)/(55:6)/(55:7)/ 
(55:8)/(55:9)/(56:6)/(56:7)/ (56:8)/(56:9) 
Cholesteryl Esters 
CE(x:y) 
14 CE  
(16:0)/(16:1)/(17:0)/(17:1)/(17:2)/(18:1)/(18:2)/(18:3)/(19:2)/
(19:3)/(20:4)/(20:5)/(22:5)/(22:6) 
 
Abbreviations: 
-O-, acyl-alkyl; 
PC, phosphatidylcholine; LPC: lyso- phosphatidylcholine; SM, sphingomyelin; 
Cer: ceramide; AC: acylcarnitine; DG: diglyceride; TG: triglyceride; CE: cholesteryl ester; 
DC, decarboxyl groups; OH, hydroxyl groups; 
x:y, x is the number of carbons and y is the number of double bonds in the fatty acid side chain 
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R Packages  
Table A6: R packages used in this thesis work. R package source: Comprehensive R Archive 
Network. 
R3.5.1 was used in this project 
Boruta v6.0.0 caret v6.0.80 
CoxBoost v1.4 dplyr v0.7.8 
e1071 v1.7-0 ggcorrplot v0.1.2 
ggplot2 v3.1.0 ggpubr v0.2 
ggrepel  v0.8.0 ggsignif v0.4.0 
glmnet v2.0.16 gmodels v2.18.1 
gridExtra v2.3 gtools v3.8.1 
Hmisc v4.2.0 penalized v0.9.51 
peperr v1.1.7.1 pROC v1.13.0 
randomForest v4.6-14 ROCR v1.0.7 
survival v2.43.1  
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Supplementary Figures 
 
Figure A1: Coefficient of variation of triplicate samples from five healthy controls and five 
ovarian cancer patients. Metabolite with a coefficient of variation larger than 0.3 is marked 
(SM C22:3). 
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Figure A2: Age is unequally distributed among MBC patients, PBC patients, OVCA patients, 
and healthy controls, especially in the validation cohort.    
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Figure A3: Associations between age (continuous) and metabolite concentrations plotted as 
−log10(p-values) for healthy control individuals in discovery and validation cohorts. The 
dashed line shows a statistical significance level (p = 0.05). The p-values were derived from 
partial spearman correlation adjusted for BMI, alcohol, sports, and smoking status. 
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